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ABSTRACT 
LIV-1, a zinc transporter, is an effector molecule downstream from soluble growth factors.  This 
protein has been shown to promote epithelial-to-mesenchymal transition (EMT) in human pan-
creatic, breast, and prostate cancer cells.  Despite the implication of LIV-1 in cancer growth and 
metastasis, there has been no study to determine the role of LIV-1 in prostate cancer progression.  
Moreover, there is no clear delineation of the molecular mechanism underlying LIV-1 function 
in cancer cells.  In this study, we found increased LIV-1 expression in a progresssive manner in 
benign, PIN, primary and bone metastatic human prostate cancer.  We characterized the mecha-
nism by which LIV-1 drives prostate cancer EMT in an androgen-refractory human prostate can-
cer cell (ARCaP) bone metastasis model.  LIV-1, when overexpressed in ARCaPE cells (deriva-
tive cells of ARCaP with epithelial phenotype), promoted EMT irreversibly.  LIV-1 overex-
pressed ARCaPE cells had elevated levels of HB-EGF and matrix metalloproteinase (MMP) 2 
and MMP 9 proteolytic enzyme activities, without affecting intracellular zinc concentration.  The 
activation of MMPs resulted in the shedding of heparin binding-epidermal growth factor (HB-
EGF) from ARCaPE cells, eliciting constitutive epidermal growth factor receptor (EGFR) phos-
phorylation and its downstream extracellular signal regulated kinase (ERK) signaling.  Further 
investigation of the HB-EGF promoter revealed that both Stat3 and AP-1 controlled HB-EGF 
promoter activity. Ectopic LIV-1 overexpression induced AP-1 and Stat3 activation. Blockade of 
both Stat3 and AP-1 by specific inhibitors or dominant negative expression vectors diminished 
the HB-EGF promoter activity induced by LIV-1 overexpression. These results suggest that LIV-
1 is involved in prostate cancer progression as an intracellular target of growth factor receptor 
signaling which promotes EMT and cancer metastasis.  LIV-1 could be an attractive therapeutic 
target for the eradication of pre-existing human prostate cancer and bone and soft tissue metasta-
ses. 
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1 
1 INTRODUCTION 
1.1 Prostate cancer 
 
Prostate cancer is the most commonly diagnosed cancer and second leading cause of can-
cer-related death in men in the United States. The American Cancer Society estimated that more 
than 217,730 new cases of prostate cancer were diagnosed and over 32,050 men died of the dis-
ease in 2010 (Bubendorf et al., 2000; Keller et al., 2001).  Roughly 1 man in 6 will be diagnosed 
with prostate cancer during his life time and 1 in 36 will die of prostate cancer. If prostate cancer 
is detected at an early stage, curative treatment by radical prostatectomy or radiotherapy is possi-
ble (Bagshaw et al., 1994; Zincke et al., 1994). However, once prostate cancer metastasizes the 
mortality rate is extremely high.   
The prostate is a gland which belongs to the male reproductive system and produces fluid 
for semen. The main cell types of the prostate epithelium are the basal, secretory glandular and 
neuroendocrine cells. The glandular cells secret PSA and prostatic acid phosphatase into the 
glandular lumina and are the major cell type in normal and hyperplastic epithelium. The secreto-
ry glandular cells have high AR expression and thus are androgen-dependent for their growth. In 
contrast, basal cells express low or undetectable AR and locate on the basement membrane. Neu-
roendocrine cells also locate on the basement membrane and both basal and neuroendocrine cells 
are androgen insensitive. Almost all prostate cancers develop from secretory epithelial cells of 
the prostate gland and often grow slowly within the gland. It is believed that high grade prostatic 
intraepithelial neoplasia (HGPIN) is a precursor of prostate cancer. PIN, first described in 1969 
(McNeal, 1969), is a neoplastic proliferation of prostatic epithelial cells. Over time, these cancer 
2 
cells begin uncontrolled proliferation to form a tumor. Eventually, the tumor cells may gain mi-
gratory and invasive ability and invade surrounding tissue, circulate in the bloodstream and lym-
phatic system, and finally colonize at metastatic sites.  
PIN glands characteristically contain basal cells around their periphery (Figure 1.1). The 
presence of basal cells is an indicator differentiating PIN from prostatic adenocarcinoma in 
which the basal cells are absent. Normal prostate, PIN, and prostatic carcinoma can be easily dis-
tinguished using specific basal cell marker (p63) and the prostate cancer marker Alpha-
methylacyl-CoA racemase (AMACR), since AMACR is expressed at a much higher level  in ad-
enocarcinoma than in non-neoplastic prostatic glands. Typically, normal prostate only shows ba-
sal cell staining, whereas prostate carcinoma only shows AMACR marker staining. However, 
HGPIN exhibits both markers, which is different from normal prostate or adenocarcinoma 
(Zynger and Yang, 2009). 
Early prostate cancer usually has no symptoms and is usually diagnosed by a PSA test. If 
the prostate cancer is confined within the gland, radical prostatectomy is potentially curative. 
However, prostate cancers that have spread outside the gland are typically treated with hormone 
therapy. Hormone therapy, also called androgen deprivation therapy, aims to reduce levels of 
testosterone and dihydrotestosterone.  Castration induces apoptosis of the majority of prostate 
cancer cells and causes tumors to shrink or grow more slowly. Most prostate cancers will have 
an initial favorable response to hormone therapy, hobut over time prostate cancer cells adapt to 
the low androgen environment and start to grow again. As the cancer progresses, prostate cancer 
cells gradually become androgen-independent and stop responding to hormone therapy. Chemo-
therapy is given if prostate cancer has already metastasized and hormone therapy fails. However, 
patients with metastatic prostate cancer are not curable and usually die within 1-2 years. A fuller 
3 
understanding of the mechanisms underlying cancer metastasis is vital for developing new thera-
peutic drugs. 
 
1.1.1 Tumorigenic signaling pathways in prostate cancer 
 
Androgen signaling. Androgen and androgen receptor (AR) both play critical roles in 
normal prostate development as well as prostate cancer(Suzuki et al., 2003). For example, trans-
genic mice engineering express high levels of the AR in the prostate tend to develop 
PIN(Stanbrough et al., 2001). AR is a ligand-activated transcription factor which belongs to a 
steroid hormone receptor family. AR controls the expression of numerous mitotic gene products, 
such as PSA, c-fos, Drg-1 and caveolin-1, which are important for the normal and neoplastic de-
velopment of the prostate. In vitro studies showed that AR activation leads to stimulation of the 
survival signals and metastatic potential in LNCaP cells treated with androgen (Li et al., 2001; 
Torring et al., 2003). As cancer progresses, prostate cancer changes from androgen-dependent to 
androgen-independent. Many mechanisms have been proposed and changes of AR signaling are 
believed to play a crucial role. In androgen-independent prostate tumors, the aberrant AR activa-
tion may be due to AR amplification, AR mutation, ligand-independent receptor activation, and 
an increase of co-activator expression or decrease of co-repressor expression. In fact, AR ampli-
fication has been found in 20-30% of hormone refractory patients(Koivisto et al., 1998). Increase 
of AP expression allows cancer cells to survive in a low or depleted androgen environment. Over 
80 mutations of AR have been identified, and most of them are mutated in the transactivation 
domain or ligand-binding domain, thus causing gain-of-function mutations(Gottlieb et al., 2004). 
In a transgeneic model, AR wild type and AR mutants were specifically introduced into mice 
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prostate(Han et al., 2005). Only AR mutants caused development of prostate cancer, but not wild 
type AR, addressing the importance of AR mutations. In addition, AR activity could be activated 
in the absence of androgen by several growth factor cascades, including EGF, IGF-1, KGF, IL-6 
and PKA pathway (Culig et al., 1994; Grossmann et al., 2001; Ueda et al., 2002). These factors 
are ligands for receptor tyrosine kinases and activation of these pathways may stimulate AR acti-
vation and promote growth of cancer cells in a low androgen environments. Furthermore, an in-
crease of coactivator expression is another mechanism which causes AR activation(Gregory et 
al., 2001). In vitro studies showed that overexpression of AR coactivator enhance AR activity to 
low levels of androgen.  In clinical specimens, AR coactivators- transcriptional factor 2, steroid 
receptor coactivator 1, and nuclear receptor coactivator amplified in breasrt cancer 1-have been 
shown to enhance expressions along with increases of AR expression in androgen-independent 
prostate cancer. Thus increases of coactivator expressions enhanced AR reponses similar to AR 
mutation.  
Wnt/β-catenin signaling cascades. The aberrant activation of the canonical Wnt/β-catenin 
signaling pathway also contributes prostate cancer progression. In the absence of Wnt signaling, 
free cytoplasmic β-catenin is quickly turned over by a destruction complex consisting of the ade-
nomatous polyposis coli protein (APC), axin, glycogen synthase kinase 3-beta (GSK3β) and ca-
sein kinase Iepsilon(CKI)17, 18. CKI and GSK3β phosphorylate N-terminal serine/threonine res-
idues of β-catenin(Amit et al., 2002; Liu et al., 2002). The phosphorylated β-catenin is targeted 
by an E3 ubiquitin ligase called β-TrCP (beta-transducin repeat-contain protein) and then de-
graded.  Binding of Wnt molecules to the Frizzled-LRP5-LRP6 receptor complex leads to the 
inhibition of this degradation complex. Therefore, free cytoplasmic β-catenin is stabilized, accu-
mulates in the cytosol and translocates to the nucleus. Nuclear β-catenin acts as a transcriptional 
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activator in a complex with the LEF/TCF DNA binding proteins (Behrens et al., 1996; Korinek 
et al., 1997; van Noort and Clevers, 2002). TCF/LEF molecules bind to promoter regions of tar-
get genes in a sequence-specific manner by recognizing the consensus sequence motif T/A T/A 
CAAAG24. In the absence of nuclear β-catenin, TCF/LEF usually binds to members of the 
groucho/TLE proteins which are transcriptional repressors, thus causing inhibition of transcrip-
tion of target genes. When β-catenin enters the nucleus, it displaces groucho/TLE proteins and 
binds to LEF/TCF to increase transcription of target genes including regulators of cell cycle, cell 
proliferation and metastasis (Daniels and Weis, 2005; Gavert and Ben-Ze'ev, 2007)(Figure 1.2). 
Several Wnt ligands have been reported to express at significant levels in prostatic stromal cells, 
androgen-dependent and independent cell linesn and tumor tissues (Chen et al., 2004; Zhu et al., 
2004). Moreover, high levels of Wnt-1 and β-catenin were detected in 77% of patients with 
lymph node metastasis and 85% in skeletal metastasis, suggesting the significant of this pathway. 
Hedgehog signaling cascades. Abnormal hedgehog signaling has also found to cause can-
cer. The expression of hedgehog signaling components were found to be up-regulated in prostate 
cancer cells compared to normal prostate tissue. Increases of sonic hedgehog ligand, SHH, lead 
to the activation of the GLI-1 transcription factor which controls tumorigenic genes of cyclin D1 
and c-Myc, resulting in sustaining growth of prostate cancer cells (Fan et al., 2004; Karhadkar et 
al., 2004; Sanchez et al., 2004).  
Cytokine signaling cascades. The up-regulation of several cytokines in the serum of pros-
tate cancer patients seems to be associated with the development of more malignant types of 
prostate cancer. For instance, higher expression of IL-6 appears in serum and tissues from pa-
tients with high grade prostate cancer, and is associated with poor patient outcome (Culig et al., 
2005; Hobisch et al., 2001). In addition, Il-6 has been reported to mediate ligand-independent 
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activation of AR in androgen-independent prostate cancer cells, suggesting a role in promoting 
androgen-independent progression of prostate cancer (Yang et al., 2003). TGF-β has also been 
found to have high levels in serum of patients with advanced prostate cancer. TGF-β has dual 
functions in prostate. TGF-β inhibits the growth of normal prostate epithelial cells, but can pro-
mote EMT and metastasis in advanced prostate cancers (Bhowmick et al., 2004). Thus, targeting 
of these tumorigenic signaling pathways may provide a good therapeutic benefit.  
 
1.1.2 Tumor microenvironment 
 
The interactions between epithelial cells and their microenvironment are crucial in nor-
mal prostate development and adult function. Disregulation of stromal-epithelial interactions has 
been suggested to contribute to malignant progression and tumorigenesis (Hayward et al., 1996; 
Hayward et al., 1998; Hayward et al., 1997). In particular, the interaction of tumor cells with 
platelets, lymphocytes, fibroblasts, and marcrophages was proved to be involved in tumor pro-
gression. The interaction between tumor cells and host cells is reciprocal. First, tumor cells may 
secret some soluble factors, such as TGF-β and PDGF, to induce stromal fibroblasts to undergo 
myofibroblast transition, a process shared by wound healing and tumorigenesis. Tuxhorn et al. 
provided evidence that prostate cancer epithelium induced fibroblast-to-myofibroblast transition 
with an increase of α-smooth muscle actin, vimentin, and calponin expressions, which are char-
acteristic of the myofibroblast phenotype, in the surrounding stroma (Tuxhorn et al., 2002). Evi-
dence shows that myofibroblasts are also crucial for cancer cell progression. Chung et al. demon-
strated that co-inoculation of prostate cancer cells and normal stromal fibroblasts from the fetal 
urogenital sinus inhibits the growth of cancer cells. In contrast, prostate cancer cells inoculated 
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with cancer-associated myofibroblasts show enhanced growth and metastatic potential, suggest-
ing a role for myofibroblasts in cancer progression (Chung et al., 1989). In addition, cancer-
associated stroma may release cytokines or neuroendocrine factors, such as HGF, VEGF, IGF-1 
and IL-6, which may stimulate cancer cell invasiveness, angiogenesis, and tissue remodeling. Cat 
et al. showed that myofibroblasts can be induced by tumor cell-derived TGF-β, with an increased 
release of HGF, VEGF, and IL-6 (Cat et al., 2006), which have been shown to be involved in 
EMT and androgen-independent progression. In vivo studies also demonstrated that tumor 
growth and metastasis is significantly reduced in fibroblast-deficient mice. In summary, cancer 
cells not only produce some factors which favor their survival and growth, but also secret factors 
which may promote host stromal cells produce more effectors which in turn act as tumor stimu-
lators to enhance the invasiveness of tumor cells. Thus, a better understanding of stromal-
epithelial interactions would be expected to reveal novel therapeutic options. 
 
1.2 EMT 
1.2.1 The concept of EMT 
 
Epithelial-to-mesenchymal transition (EMT) is a phenomenon by which epithelial cells 
acquire migratory and invasive potential during physiological and pathological processes such as 
embryonic development, wound healing, and cancer progression. Epithelial cells and 
mesenchymal cells are distinguished by their unique visual appearance. Epithelial cells are ad-
herent cells and they attach laterally to each other to form a sheet of cells called an epithelium. 
Cell-to-cell junctions and adherent proteins hold neighboring epithelial cells tightly together and 
restrain epithelial cells from moving away from the epithelium. A typical epithelium is one cell 
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thick and is polarized along an apical-basal axis where the basal surface interacts with basal 
membrane. In addition, the intracellular cytoskeleton network maintains the cell structure and 
provides rigidity and polarization. In contrast, mesenchymal cells are non-polarized and have a 
diffuse network; therefore they are irregular in shape and less rigid, accounting for the increased 
migratory ability.  
The concept of “Epithelial-Mesenchymal Transformation” was first described by Eliza-
beth Hay in 1995 using the chick primitive streak as a model (Hay, 1995). Hay proposed that 
epithelial cells can undergo dramatic changes and transform into mesenchymal cells during em-
bryonic development. Since it is clear that EMT is a reversible process and mesenchymal cells 
can revert back to epithelial phenotype, termed “Mesenchymal-Epithelial Transiton” (MET), the 
term of “Epithelial-Mesenchymal Transformation” has been replaced with “Epithelial-
Mesenchymal Transition”. 
Turning epithelial cells into mesenchymal cells requires profound changes in epithelial 
cell organization (Kalluri, 2009; Kalluri and Weinberg, 2009). First, epithelial cells need to dis-
assemble the cell-cell junctions and lose their apical-basal polarity. Cell surface proteins like E-
cadherin which mediate epithelial cell to epithelial cell concection are replaced by N-cadherin 
which provides weaker adhesive properties, allowing cells to adopt the mesenchymal phenotype. 
In addition, cytoskeletal networks are reorganized and the cytokeratin intermediate filaments are 
replaced by vimentin. These changes convert the cell from a cuboidal to a spindle shape and are 
crucial for cells to leave the epithelium and begin to migrate individually. Second, in order to 
migrate and invade into the extracellular matrix, cells need to express proteases that degrade ex-
tracellular matrix simultaneously. Thus, upon undergoing EMT, cells lose epithelial cellular po-
larity, detach from their primary site and acquire migratory and invasive properties, allowing 
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them to migrate through the extracellular matrix (Rorth, 2009). Once arriving at their destination, 
these mesenchymal cells may undergo the reverse process of MET and establish themselves as 
one of many possible cell types. In summary, the characteristics of EMT are a loss of epithelial 
marker expressions, particularly E-cadherin, and an increase in mesenchymal marker expressions, 
such as N-cadherin, vimentin and fibronectin.    
 
1.2.2 EMT during embryonic development 
 
EMT happens in many biological and pathological events such as embryonic develop-
ment, normal tissue repair and wound healing, and cancer progression. Primary EMT takes place 
during the implantation of the embryo, gastrulation, and organ development. During embryonic 
implantation, the trophoectoderm cells undergo EMT to invade into the endometrium and anchor 
in the placenta (Pijnenborg et al., 1980).  
Gastrulation is a process by which the initial epithelial layer-epiblast forms a three grem 
layer, the ectoderm, the endoderm, and mesoderm. During gastrulation, the first EMT is the 
breakdown of the basement membrane underlying the epiblast. Cells in the primitive streak un-
dergo EMT, resulting in the ingression of these cells within the primitive streak. The ingressing 
cells then either undergo MET to form the endoderm or remain mesenchymal to form the meso-
derm.   
Another example of primary EMT happens during neural crest formation. Epithelial cells 
of the neuroectoderm undergo EMT and generate a group of migratory neural crest cells (Tucker, 
2004). These migratory neural crest cells disperse throughout the embryo and give rise to differ-
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ent cell types including the neurons of the peripheral nervous system, pigment cells, and the cells 
of the adrenal medulla. 
1.2.3 EMT during tissue regeneration and fibrosis 
 
Inflammatory cells and fibroblasts mediate the release of inflammatory agents as well as 
components of extracellular matrix including collagens, fibronectins, elastin, and tenacins. Under 
pathological conditions, these stromal cells release inflammatory signals to stimulate normal epi-
thelial cells undergoing EMT. Such EMT is found to be associated with progressive fibrotic dis-
eases of the kidney, liver, heart, lung, and intestine (Kim et al., 2006; Potenta et al., 2008; 
Zeisberg et al., 2007a; Zeisberg et al., 2007b). Many studies used fibroblast-specific protein 1 
(FSP1), α-SMA, and collagen I as mesenchymal markers for the EMT that occurs during fibrosis 
(Okada et al., 1997; Strutz et al., 1995). The expression of these markers was found to be corre-
lated with the prognosis and extent of fibrosis. Such cells express FSP1 mesenchymal marker 
and α-SMA, but these cells still display epithelial morphology as well as E-cadherin. The behav-
ior of these cells indicates that under inflammatory stimuli, epithelial cells can have different de-
grees of EMT, termed “partial EMT”. These cells then leave the epithelial layer and eventually 
accumulate in the tissue with a loss of all the epithelial markers and gain of a fully fibroblastic 
phenotype (Okada et al., 1996). 
 
1.2.4 EMT during cancer progression 
 
Most cancer deaths are due to metastatic tumors instead of the primary tumor. Metastasis 
is the spread of cancer cells which leave the site of primary tumors and disseminate to distant 
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sites. The process of metastasis in epithelial cancer consists of multiple steps. First, cancer cells 
lose cell-cell contact, become motile and gain the ability to invade to surrounding tissue. Once 
the cancer cells escape the basement membrane, they intravasate into local blood vessels, circu-
late through the blood stream, extravasate from the blood vessel and finally colonize at the sec-
ondary site (Chambers et al., 2002; Woodhouse et al., 1997). Metastasis will not happen if any of 
these steps fail (Figure 1.3).  
Accumulated evidence indicates that EMT is associated with cancer progression (Thiery, 
2002). EMT phenomena have been observed in many cancers, including breast, pancreatic, ovar-
ian, colon, lung, esophageal and prostate. The characteristics of oncogenic EMT include disas-
sembly of tight junctions and adherent junctions, loss of apical-basal polarity, cytoskeleton rear-
rangement, and a gain of mesenchymal phenotype with increased migratory and invasive proper-
ties. The process of EMT during cancer progression and metastasis closely parallels develop-
mental EMT. Numerous EMT inducers in cancer cell lines have been indentified including 
Transforming Growth Factor-β (TGF-β), Wnt, Snail/Slug, Twist and Six1, and these abnormally 
expressed EMT inducers are also critical during developmental EMT. Extensive mouse studies 
and cell line experiments have demonstrated that cancer cells can undergo EMT and acquire mi-
gratory and invasive properties when treated with EMT inducers. Blocking specific regulators 
could revert the mesenchymal phenotype as well as suppress invasive ability. Moreover, cells 
exhibiting EMT properties are often seen at the invasive front of primary tumors where EMT is 
likely to be induced by exposure to cytokines or extracellular stimuli. These cells are considered 
to be the ones that eventually invade the surrounding stroma and spread to distant sites. Thus, 
EMT is thought to be a critical mechanism for the metastatic spread of cancer cells. In addition, 
clinical studies have also suggested that EMT inducers in cancer correlate with poor clinical out-
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come and tumor malignancy. However, phenotype changes in EMT are much more difficult to 
observe in vivo, since only a subset of tumor cells may undergo EMT at any one time. The main 
argument for the lack of a role of EMT in cancer is that from a histopathological point of view, 
metastatic tumors seem no different from the primary tumors. Therefore, the significance of 
EMT in cancer metastasis is still being debated (Christiansen and Rajasekaran, 2006; Garber, 
2008; Thompson et al., 2005). 
Recently, circulating tumor cells isolated from patients with progressive metastatic solid 
tumors, with a focus on men with castration-resistant prostate cancer (CRPC) and women with 
metastatic breast cancer (BC), were found to coexpress both epithelial and mesenchymal markers, 
suggesting that EMT processes indeed exist in clinical CTC (Armstrong et al.). In addition, EMT 
cells and non-EMT cells both are required for metastasis (Tsuji et al., 2009). When only EMT 
cells or only non-EMT cells were subcutaneously injected, no metastasis was observed. EMT 
cells could be found in the blood stream, but failed to colonize a secondary site. Metastatic tumor 
was observed only when both EMTand non-EMT cells were co-injected. Moreover, metastasis 
was observed when non-EMT cells were i.c injected into mouse tail vein, but not EMT cells. 
These findings suggest that EMT cells are responsible for invasion into the circulation, and only 
non-EMT cells are able to colonize at secondary sites. EMT cells and non-EMT cells need to co-
operate in order to metastasize. Thus, EMT is now considered to play a critical role in the inva-
sive steps of the metastatic cascade, causing invasive metastatic spread of tumors. 
 
1.2.5 Molecular mechanism of EMT 
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E-cadherin regulation. One of the most important characteristics of EMT is the loss of 
cell-cell adhesion with down regulation of epithelial cadherin (E-cadherin). E-cadherin, a calci-
um-dependent transmembrane protein, is the most important adhesion molecule in epithelial cells. 
The intracellular part of E-cadherin is linked to the actin cytoskeleton through interaction with β-
catenin. The extracellular part of E-cadherin binds to the binding sites of other E-cadherin on ad-
jacent cells. Cadherin-cadherin binding is strong and serves as a major cell-cell adhesion force. 
The cadherin-catenin complex is essential for cell architectural integrity. Disruption of either of 
the complex components causes significant changes in cellular behavior and often results in 
tumorigenesis. Cadherin-mediated cell-cell adhesion is highly dynamic, enabling the reorganiza-
tion and dispersal of cells. E-cadherin has been extensively studied in human epithelial cancers 
and loss of E-cadherin expression results in tumor progression, metastasis, and poor prognosis in 
various human cancers (Chan et al., 2003; Dorudi et al., 1993; Gould Rothberg and Bracken, 
2006; Kowalski et al., 2003). 
Transcription factors. Multiple mechanisms of E-cadherin loss have been demonstrated, 
including transcriptional, genetic or epigenetic changes that cause a functional loss of E-cadherin. 
The loss of E-cadherin expression at the transcriptional level was first identified in several cancer 
cell lines as well as human cancers, including prostate, breast, colorectal, lung, pancreatic, and 
thyroid cancers (Strumane et al., 2004; Van Aken et al., 2001). Later, the E-box response ele-
ments in the proximal E-cadherin promoter which determine epithelium-specific expression and 
sites of repressor binding were identified (Behrens et al., 1991; Rodrigo et al., 1999). Importantly, 
several developmental important transcription factors that induce EMT also repress E-cadherin 
during tumor progression. These transcription factors includes the snail family of zinc finger pro-
teins (Snail, Slug), zinc finger proteins (ZEB1, ZEB2), and bHLH protein (Twist), which can 
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directly bind to E-cadherin promoter to repress E-cadherin expression (Batlle et al., 2000; Cano 
et al., 2000; Comijn et al., 2001; Eger et al., 2005). Among them, Snail is one of the key regula-
tors of EMT. Overexpression of Snail reduces not only E-cadherin and other adhesion molecules 
but also induces mesenchymal markers to promote EMT and mesenchymal phenotype (Cano et 
al., 2000). In addition, Snail expression could be up-regulated by many known oncogenic signal-
ing pathways, such as transforming growth factor-β (TGF-β) receptor pathway, epidermal 
growth factor (EGF) receptor pathway, and fibroblast growth factor (FGF) pathway. Furthermore, 
abnormal expressions of these transcriptional repressors have been found in many human cancers. 
During EMT, these transcriptional repressors not only suppress E-cadherin expression but also 
repress other adhesion molecules and induce mesenchymal phenotype (Aigner et al., 2007; De 
Craene et al., 2005; Vandewalle et al., 2005). 
Genetic and epigenetic control. Besides transcriptional control, E-cadherin can be regu-
lated by genetic or epigenetic mechanisms. Mutations of E-cadherin are found in gastric cancer 
(Becker et al., 1994; Brooks-Wilson et al., 2004) and lobular breast cancer (Sarrio et al., 2003). 
E-cadherin promoter polymorphism is potentially a good marker for the risk of bladder cancer 
recurrence (Lin et al., 2006). In addition, hypermethylation of the E-cadherin promoter region is 
found in various human cancers, resulting in loss of e-cadherin expression (Graff et al., 1995; 
Yoshiura et al., 1995). Furthermore, the extent of methylation of the E-cadherin region during 
cancer progression is unstable and heterogeneous, suggesting that methylation may induce EMT 
through downregulation of E-cadherin expression to promote metastatic progression (Graff et al., 
1995). 
microRNAs. Recently, small non-coding RNAs of 20-22-nucelotides (microRNAs) that 
inhibit gene expression at the post-transcriptional level have been identified to play a role in the 
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regulation of EMT. The miR-141, miR-200b, and miR-205 families are critical controls in ZEB1 
and ZEB2 expression, leading to EMT regulation (Gregory et al., 2008; Park et al., 2008). Selec-
tive knockdown of miR-141, miR-200b, and miR-205 family miRNAs was sufficient to suppress 
E-cadherin expression and induce EMT in MDCK3 and HCT116 cells. Additionally, overex-
pression of these miRNAs results in E-Cadherin re-expression and MET in mesenchymal cells. 
The mechanisms of microRNA involvment in EMT need to be elucidated in more detail. 
 
1.2.6 Extracellular signals and intracellular networks regulating EMT 
 
Interaction between cancer cells and the tumor microenvironment profoundly influences 
the behavior of cancer cells. The tumor microenvironment is composed of ECM, cancer-
associated fibroblast, myofibroblast, and immune cells. EMT is observed particularly at the inva-
sive front, suggesting that the microenvironment plays a critical role in regulating EMT(Le et al., 
2008). EMT can be induced by growth factors, cytokines, or ECM proteins secreted by the mi-
croenvironment. For example, conditioned media from cancer-associated fibroblasts induce 
EMT in breast cancer cells (Lebret et al., 2007). In addition, TGF-β signaling by stromal 
myofibroblasts can induce secretion of hepatocyte growth factor which promotes cancer cell pro-
liferation and invasion (Lewis et al., 2004).  
EMT regulators. Cell signaling pathways are critical inducers of EMT through transcrip-
tional or post-transcriptional induction of several EMT transcription factors, including Snail, 
Slug, twist, ZEB1, and ZEB2. A variety of extracellular signals have been shown to induce EMT 
in cancers. TGF-β, EGF family members, FGF, HGF, and IGF have all been shown to trigger 
EMT in an autocrine or paracrine manner (Huber et al., 2005). One of the most potent and best 
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studied EMT inducers is TGF-β. The TGF-β family of cytokines binds to transmembrane recep-
tor serine/threonine kinases which in turn activate cytoplasmic Smads (Massague et al., 2005). 
Activated Smads translocate to the nucleus and activate e-cadherin repressors of the Snail family. 
TGF-β has dual roles. TGF-β inhibits the growth of normal epithelial cells, but can promote can-
cer progression at certain stages through its ability to induce EMT (Shi and Massague, 2003; 
Siegel and Massague, 2003). In vitro studies showed that TGF-β induced EMT in many types of 
cancer cells with a loss of cell-cell adhesion and cell polarity, and gain of mesenchymal pheno-
type (Ozdamar et al., 2005; Peinado et al., 2003; Zavadil and Bottinger, 2005; Zhao et al., 2008). 
In early stage breast cancer, TGF-β is a tumor suppressor through its growth inhibitory effect 
(Reynisdottir et al., 1995). In contrast, TGF-β promotes metastasis in later stages of breast cancer, 
at least in part through its ability to induce EMT(Muraoka-Cook et al., 2006; Muraoka et al., 
2002). In vivo, TGF-β also enhanced tumor aggressiveness in a mouse model (Muraoka-Cook et 
al., 2006) and blockade of TGF-β reduced metastasis and primary tumor growth in a mouse 
model (Siegel et al., 2003). In addition, clinical studies also support a positive correlation be-
tween expression of TGF-β ligands and poor prognosis (Ghellal et al., 2000; Mu et al., 2008). 
Wnts, a large family of cysteine-rich, secreted lipid-modified signaling proteins, are po-
tent regulators of cell proliferation and differentiation (Willert et al., 2003). The Wnt/β-catenin 
pathway is implicated in EMT during development and cancer (Logan and Nusse, 2004; Reya 
and Clevers, 2005). Loss of function in Wnt signaling leads to developmental abnormalities, 
whereas constitutively active Wnt signaling causes tumorigenesis (Polakis, 2007; Taipale and 
Beachy, 2001). In vitro studies showed that activation of the Wnt pathway induces EMT by 
upregulating Snail expression in numerous cancer cell lines (Gilles et al., 2003; Kim et al., 2002). 
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Furthermore, active Wnt signaling also clinically correlates with poor outcome in breast cancer 
patients (Logullo et al., ; Prasad et al., 2009).  
 
1.3 LIV-1 
1.3.1 LIV-1 belongs to LIV-1 subfamily of ZIP transporters 
 
Zinc is an essential metal for all cells and plays an important role in a variety of physio-
logical and biochemical processes, including gene expression, growth, metabolism, development, 
and differentiation (Vallee and Falchuk, 1993). Zinc deficiency is associated with diverse disor-
ders, such as impaired immunity, retarded growth, brain development disorders, delayed wound 
healing, retarded skeletal development, and development of osteoporosis (Andrews and Gal-
lagher-Allred, 1999; Eberle et al., 1999; Hall et al., 1999; Nishi, 1996; Rink and Gabriel, 2000). 
Therefore zinc homeostasis needs to be tightly controlled. Zinc cannot passively diffuse across 
cell membranes because of its charges, so two families of mammalian zinc transporters are re-
quired to transport zinc across cell membranes: ZnT (Zinc transporter) proteins and the Zip (Zrt 
and Irt-like) proteins. They have opposite functions in cellular zinc transportation. ZnT trans-
porters are responsible for transporting zinc out of cells to reduce intracellular zinc, whereas ZIP 
transporters promote zinc uptake to increase intracellular zinc. Normal prostate gland accumu-
lates high levels of citrate and zinc compared to other tissues. Zinc accumulation by the prostate 
epithelial cells is achieved through the ZIP family of zinc uptake transporters. The ZIP family 
contains four subfamilies(Guerinot, 2000). Subfamily I is mainly fungal and plant sequences, 
while subfamily II consists of mammalian, nematode and insect genes. The gufA subfamily is 
related to the gufA gene of Myxococcus Xanthus which has unknown function, and the LIV-1 
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subfamily. 15 members of ZIP family proteins have been identied, but only a few of them have 
been functionally characterized. Among them, hZIP1 has been proposed to be the major zinc 
transporter for many tissues (Gaither and Eide, 2001; Guerinot, 2000). In addition, hZIP1 has 
been demonstrated to have constitutive expression in normal prostate cells and function in the 
uptake and accumulation of zinc in prostate cells (Franklin et al., 2003). Clinical and experi-
mental studies showed that hZIP1 gene expression is down regulated and zinc is depleted in 
maglignant prostate compared to normal prostate (Franklin et al., 2005a). Furthermore, overex-
pression of hZIP results in decrease of malignancy of prostate cancer cells in vitro and in vivo 
(Golovine et al., 2008; Huang et al., 2006a).  
LIV-1, which was originally identified as an estrogen-regulated gene in metastatic breast 
cancer, has been characterized as a new subfamily of ZIP zinc transporters termed LZT(el-
Tanani and Green, 1995). Based on a computer analysis of secondary structure, LIV-1 contains 
6-8 transmembrane domains, a long extracellular N terminus, a short extracellular C terminus, 
and a consensus sequence for a catalytic zinc-binding site of metalloproteases (HEXPHE) with a 
molecular mass of 84 kDa (Taylor et al., 2003; Taylor and Nicholson, 2003) (figure 1.4). The 
catalytic zinc is required for the proteolytic metalloprotease activity (Massova et al., 1998). Of 
interest, no other zinc transporters contain this potential metalloprotease motif, suggesting that 
LIV-1 may have different function other than transporting zinc. In addition, by using V5-tag 
LIV-1 exression vector, LIV-1 has been shown to locate on the plasma membrane, especially 
concentrating on lamellipodiae. Moreover, LIV-1 has been demonstrated to be able to transport 
zinc in human neuroblastoma cells (Chowanadisai et al., 2008). 
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1.3.2 LIV-1 is associated with EMT and cancer progression  
 
LIV-1 was first identified in the breast cancer cell line ZR-75-1 as an estrogen-regulated 
gene (el-Tanani and Green, 1995), and is predominately expressed in hormonal controlled tissues 
with high levels in breast, prostate, pituitary gland and brain (Taylor et al., 2003). In clinical 
samples, LIV-1 expression correlates with ERα in breast tumor biopsies (Dressman et al., 2001; 
Tozlu et al., 2006) and is associated with the spread of breast cancer to the regional lymph nodes 
(Manning et al., 1994), suggesting a role in metastasis.  
EMT has been implicated in the progression of many solid tumors, including prostate 
cancer (Whitbread et al., 2006; Xu et al., 2006; Zhau et al., 2008), and is considered a key mo-
lecular event in cancer progression (Thiery, 2003). LIV-1 was reported to be a downstream target 
of STAT3 and essential for the nuclear localization of Snail in zebrafish gastrula organizing cells 
for their migration (Yamashita et al., 2004). LIV-1 cooperates with Snail by binding to E-
cadherin promoter and repressing its transcription (Batlle et al., 2000).  LIV-1 mRNA was re-
cently shown to be higher in cervical cancer in situ than in normal tissues (Zhao et al., 2007a).  
RNAi mediated suppression of LIV-1 in HeLa cells significantly inhibited their proliferation, 
colony formation, migratory, and invasive ability (Zhao et al., 2007b).  LIV-1 has also been re-
ported to be elevated in clinical pancreatic carcinoma and induced EMT in pancreatic cancer 
cells (Unno et al., 2009).  However, LIV-1 expression was also reported to correlate with E-
cadherin expression(Shen et al., 2009) and to be associated with better outcome in breast cancer 
patients (Kasper et al., 2005). Although results are conflicting, LIV-1 is still thought to be an ob-
ligatory co-factor regulating EMT-associated genes. Since the potential diagnostic and prognos-
tic value of LIV-1 in human prostate cancer has not been investigated, the purpose of this study 
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is to investigate the function of LIV-1 in cancer progression and evaluate the therapeutic poten-
tial of LIV-1.  
 
1.4 EGFR (Epidermal growth factor receptor) signaling in cancer 
1.4.1 Receptor activation 
 
Epidermal growth factor receptor (EGFR; ErbB1), a 170kDA membrane protein, belongs 
to the ErbB family of receptor tyrosine kinases (RTKs), which includes HER2 (ErbB2), ErbB3, 
and ErbB4. These ErbB receptors share a common structure with an extracellular ligand-binding 
domain, a single transmembrane domain, and a cytoplasmic tyrosine kinase domain. Under un-
stimulated conditions, the ErbB receptors are present as a monomer. Upon binding of receptor-
specific ligands, the receptors undergo dimerization and cause transactivation of the intracellular 
tyrosine kinase domain in which specific residues are phosphorylated. Subsequently, intracellular 
signal proteins are recruited by the phosphrylated residues, resulting in the activation of intracel-
lular pathways, including the mitogen-activated protein kinase (MAPK) and the phosphatidylin-
ositol-3 kinase (PI-3K) pathways, which ultimately modulate gene transcription (Olayioye et al., 
2000; Yarden and Sliwkowski, 2001).  
Another mechanism to cause ErbB receptor activation is known as receptor transactiva-
tion. For example, GPCR agonists, such as endothelin-1, bombesin, and thrombin, could cause 
receptor activation through stimulating metalloproteinases which in turn cleave EGF-like ligand 
precursors, leading to phosphorylation of receptors (Carpenter, 2000; Gschwind et al., 2002; 
Gschwind et al., 2001; Prenzel et al., 1999).  In addition, cytokine has been shown to indirectly 
activate ErbB receptors through janus tyrosine kinase 2 (Jak2) (Yamauchi et al., 1997). Moreo-
21 
ver, wnt signaling has also been shown to be able to induce receptor activation through metallo-
proteinase-mediated cleavage of EGF-like ligands (Civenni et al., 2003). 
 
1.4.2 EGFR function in normal development and in cancer 
 
EGFR functions are ubiquitously expressed in multiple cellular processes including em-
bryogenesis, differentiation, survival, proliferation and tumor progression. The importance of 
EGFR in developmental processes is supported by knockout mouse experiments. EGFR knock-
out mice are embryonic lethal at day 10.5-13.5 p.c. In addition, null mutation of EGFR causes 
developmental defects in the skin, lung, pancreas, GI tract and central nervous system (Miettinen 
et al., 1995; Sibilia et al., 1998; Sibilia and Wagner, 1995; Threadgill et al., 1995).  EGFR is im-
portant not only because it has essential roles in normal physiological processes during develop-
ment, but also because it is involved in numerous types of human cancers.  The ErbB receptors 
were found to be disregulated in several malignant tumors including lung, breast, colon, squa-
mous cell cancer of the head and neck, and prostate cancer (Mendelsohn, 2002; Salomon et al., 
1995). Cancer patients whose tumors have increased expression of EGFR or ErbB2 tend to have 
a more malignant tumors associated with a poor outcome (Allred et al., 1992; Hynes and Stern, 
1994; Nicholson et al., 2001; Salomon et al., 1995; Sjogren et al., 1998; Slamon et al., 1987). 
Aberrant receptor signaling is due to receptor overexpression (Hirsch et al., 2003), receptor mu-
tation causing ligand-independent activation (Moscatello et al., 1995), or autocrine activation by 
ligand overexpression (Prenzel et al., 1999). Different studies have shown that overexpression of 
EGFR or ErbB-2 could induce both in vitro and in vivo transformations. It is thought that high 
levels of the receptor promote spontaneous dimerization, thus leading to constitutive ErbB acti-
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vation.  Many genetic alterations of ErbB receptors have been demonstrated in human cancers. 
Among those mutations, the EGFRvIII mutant receptor mutated in the extracellular domain has 
been found to occur in breast, ovarian, lung, and glioblastoma cancer and is associated with lig-
and independent EGFR activity (Kuan et al., 2001; Pedersen et al., 2001).  Moreover, EGFR ag-
onists, such as EGF, TGF-α, HB-EGF, and amphiregulin, are confirmed by  a number of studies 
to show overexpression of these proteins in a variety of solid tumors (Normanno et al., 2005a; 
Salomon et al., 1995). For example, TGF-α is frequently coexpressed with EGFR in prostate 
cancer (Seth et al., 1999), breast cancer (Umekita et al., 2000), lung, ovary, non-small cell lung 
cancer (Hsieh et al., 2000), and gastrointestinal stromal tumors (Cai et al., 1999). All these al-
terations contribute to constitutive active ErbB signaling that leads to cancer development. 
The ErbB receptors are able to activate different intracellular signaling pathways, includ-
ing the ras/raf/MAPK, PI3K/Akt, and STAT pathways (Figure 1.5). Activation of these signaling 
proteins has been shown to regulate cellular functions involved in cancer development and pro-
gression (Normanno et al., 2006). It is well known that activated MAPK promotes cell migration. 
Clinical studies demonstrated that tumors with high levels of active MAPK have a particularly 
poor prognosis (Feldkamp et al., 1999). Activation of the MAP kinase pathway is associated 
with increasing prostate cancer Gleason score and tumor stage (Gioeli et al., 1999). Overexpres-
sion of Ras enhances androgen hypersensitivity in LNCaP cells (Bakin et al., 2003b). In contrast, 
overexpression of dominant negative Ras converted androgen-independent cells back to andro-
gen-dependent status in C4-2 prostate cancer cells (Bakin et al., 2003a). The PI3K/Akt pathway 
is very important in mediating cell survival, since activated PI3K may inhibit proapoptotic mole-
cules resulting in cell survival (Datta et al., 1997). An increase of PI3K has been found in pros-
tate cancer and expression of Akt was much higher in prostate cancer tissue compared to normal 
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prostate tissue or PIN (Liao et al., 2003). In addition, PTEN, a negative regulator of PI3K signal-
ing, has been identified to frequently mutate and be inactivated in prostate cancers (Li et al., 
1997). Stat3has also been implicated in cell survival. Inhibition of Stat3 in vivo results ina  de-
crease of anti-apoptotic Bcl-XL and increased cell death (Grandis et al., 2000). Together, numer-
ous data provide strong evidence that disregulated ErbB signaling plays a crucial role in cancer 
development and metastasis.   
 
1.4.3   EGFR in angiogenesis 
 
Angiogenesis is essential for tumor growth and metastasis. It has been demonstrated that 
the ErbB receptor/ligand network regulates the process of neovascularization, in which endothe-
lial cells proliferate and undergo differentiation. On the one hand, endothelial cells themselves 
express ErbBs. On the other hand, EGFR signaling regulates the production of proangiogenic 
facors, the most potent being VEGF, in different tumor cells. For example, upon EGF treatment, 
glioma cells upregulate the secretion of VEGF (Goldman et al., 1993). Conditioned media from 
EGF-stimulated glioma cells induced tube formation of human umbilical vein endothelial cells 
(HUVECs), and this effect was blocked by an anti-VEGF antibody. In addition, EGFR activation 
was shown to regulate VEGF promoter activity in glioblastoma cells through the MAPK and 
PI3K pathways, which were independent of the hypoxia-induced HIF-1 pathway, a potent induc-
er of VEGF (Maity et al., 2000). In prostate cancer cells, EGFR was also shown to regulate ex-
pressions of angiogenic factors. In particular, EGF significantly increased the secretion of VEGF 
in prostate cancer cells, and treatment with the EGFR tyrosine kinase inhibitor gefitinib sup-
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pressed EGF-induced VEGF expression both in prostate cancer cells cultured in vitro or implant-
ed in the flank of nude mice (Bianco et al., 2004; Sini et al., 2005).   
ErbB ligands also have a direct effect on endothelial cells. Using an orthotopic nude mice 
model, TGF-α-expressing tumor cells directly induced EGFR expression in endothelial cells 
(Baker et al., 2002). Baker et al. demonstrated that only tumor-associated endothelial cells ob-
tained from EGF/TGF-α positive cancers express functional EGFR, which can be activated upon 
stimulation with either EGF or TGF-α (Baker et al., 2002). In addition, stimulation of HUVECs 
with EGF or HB-EGF resulted in an increase of EGFR phosphorylation and ERK activation (Sini 
et al., 2005). Taken together, evidence supports the idea that tumor cells may induce expression 
and activation of the EGFR pathways in endothelial cells to promote tumor-associated angiogen-
esis. Thus, a better understanding the role of the EGFR/ligand network in endothelial cell/tumor 
cell interactions will provide strategies to inhibit angiogenesis which in turn could block tumor 
proliferation, survival and metastasis. 
 
1.4.4 EGFR in bone metastasis 
 
The most common metastatic site of prostate cancer is the bone (Li et al., 2006). Nearly 
80% of advanced prostate cancer cases result in bone metastasis and generate severe pain and 
disability (Landis et al., 1999). Bone metastasis results from dysregulation of the bone formation 
and bone resorption processes. The cells responsible for bone remodeling are osteoblasts, which 
secret new bone, and osteoclasts, which dissolve bone matrix. Two factors necessary and suffi-
cient for osteoclast formation and activation are macrophage colony stimulating factor (M-CSF), 
which promotes proliferation and differentiation of pre-osteoclast cells, and RANKL, which ac-
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tivates pre-osteoclasts and is secreted by osteoblasts and bone marrow stroma cells (Boyle et al., 
2003). Cancer cells are able to synthesize many growth factors and cytokines which can lead to 
the activation of osteoclasts (Roodman, 2001). EGFR signaling involvment in the pathogenesis 
of bone metastasis was demonstrated in a clinical trial of the EGFR inhibitor gefitinib in breast 
cancer patients (von Minckwitz et al., 2005). A significant improvement in bone pain was ob-
served in patients treated with gefitinib. Evidence showed that both EGF and TGF-α are able to 
stimulate bone turnover and osteoclastogenesis in different systems (Guise et al., 1993; Ibbotson 
et al., 1983; Ibbotson et al., 1985; Zhu et al., 2007). EGFR inhibitor treatment inhibits M-CSF 
and RANKL production in bone marrow stromal cells and thus inhibits osteoclast formation 
(Normanno et al., 2005b). These data suggests that EGFR signaling regulates the ability of bone 
marrow stroma cells to induce osteoclastogenesis.  
Anti-EGFR inhibitors also have an effect on prostate cancer cells. For example, gefitinib 
treatment reduced the ability of conditioned media from prostate cancer cells to induce RANKL 
expression in osterblasts (Angelucci et al., 2006). In addition, EGFR signaling activates the ex-
pression of proteases which play an important role in metastasis. For instance, the urokinase-type 
plasminogen-activator (uPAR) and matrix matalloproteinases (MMPs) are necessary for the in-
vasive ability of tumor cells and metastasis (Guise and Mundy, 1998; Nemeth et al., 2002). 
Gefitinib treatment inhibited the expressions of uPAR and MMP-9 in prostate cancer cells, and 
reduced the metastatic potential of these cancer cells (Angelucci et al., 2006). 
 
1.4.5 EGFR as a therapeutic target 
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Cancer patients whose tumors show dysregulated EGFR or ErbB-2 tend to have a more 
aggressive disease and a poor clinical outcome. Because of the importance of ErbB receptors, a 
huge effort has been made to develop therapies that target ErbBs. Two current successful ap-
proaches have been developed: anti-EGFR monoclonal antibodies and EGFR-specific tyrosine 
kinase inhibitors (TKIs). Anti-EGFR MAbs, such as cetuximab and panitumumab, bind to the 
extracellular domain of EGFR, thus preventing the binding of EGFR ligands and activating the 
receptors (Sato et al., 1983). In contrast, TKIs, such as gefitinib and erlotinib, prevent the bind-
ing of adenosine triphosphate to the intracellular tyrosine kinase domain, thus inhibiting intracel-
lular tyrosine kinase activity and subsequent signaling (Lichtner et al., 2001).  
Both MAbs and TKIs result in decreases in the MAPK, PI3K/Akt, and Jak/Stat pathways. 
However, anti-EGFR MAbs also cause downregulaiton of EGFR expression. Cetuximab is a 
chimeric anti-EGFR MAb which is approved for treating pateients with metastatic colorectal 
cancer refractory to irinotecan-based chemotherapy. Cetuximab has higher affinity toward EGFR 
compared to TGF-α or EGF and induces EGFR internalization and antibody-dependent cell-
mediated cytotoxicity. In preclinical studies in nude mice bearing irinotecan-resistant colorectal 
tumors, cetuximab exerted strong antitumor activity (Prewett et al., 2002). However, cetuximab 
only showed a 10-20% response rate in several clinical trials (Cunningham et al., 2004; Saltz et 
al., 2004). TKIs are low molecular weight synthetic molecules which block the intracellular ki-
nase activity of EGFR. For example, Gefitinib was approved for the treatment of patients with 
locally advanced or metastatic non-small cell lung cancer after failure of both docetaxel and plat-
inum-based chemotherapies.  In phase II clinical trials, Gefitinib treatment showed a significant 
response rate in patients with advanced non-small cell lung cancer (Fukuoka et al., 2003). In sub-
sequent phase III trials, Gefitinib treatment did not improve overall survival or delay tumor pro-
27 
gression (Giaccone et al., 2004; Herbst et al., 2004). However, Gefitinib did show a significant 
response rate in a particular population of patients with specific EGFR mutation (Inoue et al., 
2009; Inoue et al., 2006). Gefitinib treatment showed a 50-70% responsive rate with great pro-
gression-free survival in tthis group of patients and gefitinib was approved in Europe for treating 
patients with advanced or metastatic non-small cell lung cancer carrying EGFR mutation. 
Anti-EGFR therapy has shown significant responses in some cancers, but no therapeutic 
response resulted in the majority of cancer patients. In fact, patients initially responsive to anti-
EGFR treatment develop drug resistance over time. Potential mechanisms of resistance to 
EGFR-targeted therapies have been proposed. For example, constitutive activation of down-
stream signaling of EGFR, such as PI3K mutations and K-ras mutations, has been demonstrated 
as one of the possible causes (Prenen et al., 2009; Sartore-Bianchi et al., 2009). In addition, acti-
vation of an alternative receptor or EGFR mutation are also possible mechanisms for the devel-
opment of resistance to anti-EGFR therapies. Thus, a better understanding of the molecular 
mechanisms of resistance to EGFR-targeted therapies will further increase our understanding of 
EGFR signaling and ultimately improve treatment strategies.    
  
1.5 The Ras/Raf/MEK/ERK cascade in cancer progression 
 
The ERK cascade is activated by a large number of extracellular stimuli. Activation of 
this cascade controls a variety of cellular processes, including proliferation, differentiation, de-
velopment, cell survival, migration, apoptosis, and oncogenic transformation (Seger and Krebs, 
1995; Torii et al., 2004; Viala and Pouyssegur, 2004; Yoon and Seger, 2006). Signaling is usual-
ly initiated by activation of a small G protein, Ras, which transmits the signal further by recruit-
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ing Raf kinase to the plasma membrane (Wellbrock et al., 2004) (Figure 1.6). Once Raf is acti-
vated, Raf transmits signaling by phosphorylating MEK and activates MEK (Ahn et al., 1991). 
Upon activation, MEKs act as dual specific kinases and phosphorylate the Tyr and Thr residues 
of ERKs, leading to ERKs activation (Seger et al., 1992). Once phosphorylated by MEKs, ERKs 
become a potent protein kinase and are able to phosphorylate a large number of downstream tar-
gets (Yoon and Seger, 2006). In particular, ERKs phosphorylate and activate a series of tran-
scription factors, such as c-fos (Murphy et al., 2002), c-jun (Morton et al., 2003), p53 (Milne et 
al., 1994), Elk1 (Gille et al., 1992), and Ets1/2(Yang et al., 1996), which play critical roles in the 
initiation and regulation of proliferation and oncogenic transformation. The inactivation of ERKs 
is mainly mediated by protein Ser/Thr phosphatases or MAPK phosphatases (Sun et al., 1993). 
MAPK phosphatases inactivate MAPKs by simultaneously removing phosphates from both Tyr 
and Thr residues, thus terminating the signaling cascade. 
 
1.5.1 ERK1/2 is necessary for cell proliferation 
 
ERK1 and ERK2 were originally identified as mitogen-stimulated phosphoproteins of 41-
45 kDa (Cooper et al., 1984; Nakamura et al., 1983). The direct involvement of ERK1/2 in the 
mitogenic response was shown by the inhibition of ERKs. Overexpression of dominant negative 
ERK1 or ERK1 siRNA inhibited fibroblast cell proliferation (Pages et al., 1993). In addition, 
treatment with MEK1/2 inhibitors which prevent ERKs from activation was shown to reduce the 
proliferation of various cell types, including fibroblasts, T lymphocytes, smooth muscle cells, 
hepatocytes and epithelial cell lines (Brunet et al., 1994; DeSilva et al., 1998; Dudley et al., 1995; 
Karpova et al., 1997; Sebolt-Leopold et al., 1999; Seufferlein et al., 1996; Talarmin et al., 1999; 
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Williams et al., 1998). In contrast, overexpression of constitutive active MEK1 led to increases 
in cell proliferation (Brunet et al., 1994; Cowley et al., 1994).The role of ERK1/ERK2 in the 
regulation of cell proliferation was further demonstrated by knockout mice experiments. Analy-
sis of Erk1-/- mice revealed that ERK1 is not required for embryonic development and does not 
affect cell proliferation rate. However, Erk2-/- mice showed a defect in tropoblast development, 
resulting in embryonic lethality. 
 
1.5.2 The ERK pathway in cancer  
 
The ERK pathway is the best studied of the mammalian MAPK pathways, and 
dysregulation of ERK signaling has been found in approximately one-third of all human cancers. 
Besides a basic role in cell proliferation, ERK signaling is involved in many other aspects of 
tumorigenesis, o the signals which activate ERK are of particular interest. ERK signaling could 
be activated by a variety of extracellular stimuli. Most cancer-associated lesions show constitu-
tive activation of ERK signaling due to overexpression of receptor tyrosine kinases, activating 
mutations in receptor tyrosine kinases, sustained autocrine or paracrine production of ligands, 
Ras mutations and Raf mutations.  
Aberrant overexpression or mutation of receptor tyrosine kinases can cause activation of 
Ras leading to upregulated MAPK signaling (Lynch et al., 2004; Stephens et al., 2004). In par-
ticular, EGFR has been found to be overexpressed  or mutationally activated in many human 
cancers (Grandis and Sok, 2004). In addition, increased EGFR ligands, such as TGF-α, HB-EGF, 
and amphiregulin, could cause constitutive activation of EGFR, which in turn stimulates ERK 
signaling (Gangarosa et al., 1997; McCarthy et al., 1995). Increased expression of EGFR ligands 
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has been observed in a variety of Ras- or Raf-transformd cell types. Moreover, approximately 
30% of human cancers showed aberrant Ras expressions resulting from amplification of ras on-
cogene or activating mutations (Flotho et al., 1999; Stirewalt et al., 2001).  Recently, it was 
shown that B-raf is frequently mutated in certain cancer types, especially melanoma (27-70%), 
papillary thyroid cancer (36-53%), colorectal cancer (5-22%) and ovarian cancer (30%) (Davies 
et al., 2002; Garnett and Marais, 2004; Libra et al., 2005). The most common B-Raf mutation is 
B-Raf (V600E) in which nucleotide 600 changes from valine to glutamic acid (Garnett and Ma-
rais, 2004). This B-Raf mutation accounts for 90% of the B-Raf mutations found in melanoma 
and thyroid cancer and causes constitutive activation of B-Raf, which leads to downstream MEK 
and ERK activation. 
 
1.5.3 ERK in cell migration and invasion 
 
Cancer cells need to gain migratory and invasive abilty to successfully metastasize to dis-
tant sites. Previous studies indicated that ERK can phosphorylate and activate myosin light-chain 
kinase leading to increased phosphorylation of the myosin light chain and enhanced cell motility 
(Klemke et al., 1997). Many growth factors have been demonstrated to enhance cell migration by 
activation of receptor tyrosine kinase involving the Ras/MAPK signal pathway (Hartmann et al., 
1994; Klemke et al., 1994). Another important target of ERK involvment in cell migration is Rho 
signaling. ERK may promote a more malignant phenotype by dysregulating Rho signaling. For 
example, ERK upregulates the AP-1 transcription factor which controls Rho signaling to pro-
mote cell migration (Vial et al., 2003).  
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Gaining the ability to invade the surrounding basement membrane is another key event 
during cancer progression. MAPKs have been shown to be able to regulate the expression of pro-
teases responsible for basement membrane degradation. In response to extracellular stimuli, 
phosphor-ERK activates some transcription factors, including AP-1. The promoters of many pro-
teases such as MMP-1, MMP-3, MMP-7, MMP-9, MMP-11, MMP-13, MMP-19, and uPA con-
tain AP-1 response elements. Because of its ability to degrade ECM, all these proteases have 
been implicated in cancer progression (Brogley et al., 1999; Gum et al., 1996; Kondapaka et al., 
1997; Mazumdar et al., 2001; Overall and Lopez-Otin, 2002; Reddy et al., 1999; Ree et al., 
1998). Furthermore, angiogenesis has been linked with the ERK pathway. In a mouse model, on-
cogenic Ras expression caused an increase of VEGF expression, which promotes angiogenesis 
and tumor maintenance (Chin et al., 1999). ERK also was found to directly activate HIF-1α and 
Sp1, which were shown to induce VEGF expression (Richard et al., 1999). Because of the im-
portance of ERK signaling, the ERK pathway has been intensely studied. A better understanding 
of this signaling process will be the key to novel strategies and new therapies.  
 
1.6 Signal transducer and activator of transcription 3 (Stat3) 
 
STATs are a family of cytoplasmic transcription factors which transmit signals to the nu-
cleus where STATs bind to specific DNA promoter sequences and regulate gene transcription. 
These transcription factors are activated by a series of extracellular signals such as cytokine, 
growth factors, and hormones that bind to specific cell-surface receptors. Upon stimulation, 
STATs become activated typically through tyrosine phosphorylation by Janus kinases (JAKs) or 
growth factor receptor tyrosine kinases such as EGFR and PDGF. STATs have also been demon-
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strated to be activated through non-receptor tyrosine kinases, such as v-src, c-src, and abl. Once 
activated, phosphorylated STATs form homodimer or heterodimer and go into the nucleus to 
regulate gene expression. 
 
1.6.1 The mechanisms of STAT activation 
  
Cytokines. STAT proteins are involved in signaling by many cytokines, such as IL-6 
family cytokines. For example, IL-6 first binds to and activates its receptors, causing receptor 
aggregation. IL-6 receptors, which lack intrinsic tyrosine kinase activity, recruit JAKs to the re-
ceptors (Ihle, 1996). JAKs not only phosphorylate themselves to become activated, but also 
phosphorylate the C-terminal of the receptors. The receptor phosphotyrosines serve as a docking 
site for recruitment of STATs (Seidel et al., 1995). STATs in turn are phosphorylated by JAKs 
and then phosphor-STATs form either homo- or heterodimers to translocate to the nucleus, 
where they bind to the promoters of target genes and induce gene expression. 
Growth factors. STATs can also be activated by numerous growth factors, including EGF 
and PDGF. Activated EGFR has been shown to be able to directly phosphorylate STAT proteins. 
In most cases, c-Src is involved in STAT activation by EGF and PDGF receptors (Chaturvedi et 
al., 1998; Chaturvedi et al., 1997; Olayioye et al., 1999; Wang et al., 2000). Inhibition of c-Src 
abrogates EGF or PDGF induced Stat3 phosphorylation, indicating that c-Src is required for EGF 
or PDGF-mediated Stat3 activation. In addition, EGFR-mediated growth of transformed epitheli-
al cells is dependent on the activation of Stat3. Inhibition of Stat3 by siRNA or dominant nega-
tive Stat3 suppressed EGF-induced cell growth (Grandis et al., 1998). It has been shown that 
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constitutive active Stat3 correlates with EGFR signaling in breast cancer cells, and inhibition of 
Stat3 resulted in apoptosis of breast cancer cells (Garcia et al., 2001; Garcia et al., 1997). 
 
 
1.6.2 Stat3 in cancer development and progression 
 
The STAT family consists of seven different members: STAT1, 2, 3, 4, 5A, 5B, and 6. 
Aberrant STAT signaling, in particular Stat3 and Stat5, results in the development and progres-
sion of human cancers such as prostate, breast, pancreas, brain, lung, and head and neck cancer 
(Bowman et al., 2000; Catlett-Falcone et al., 1999; Coffer et al., 2000; Garcia et al., 2001; Lin et 
al., 2000; Song and Grandis, 2000), by either preventing apoptosis, inducing cell proliferation, or 
both (Herrington et al., 2000). Stat3-/- knockout mice resulted in embryonic lethality, suggesting 
its role in early embryonic development. Tissue-specific gene deletions have shown that Stat3 
plays a critical role in the regulation of epithelial cell apoptosis, skin remodeling, macrophage 
inactivation, and cell growth. Constitutively activated STAT3 has been demonstrated to be able 
to induce transformation, and is associated with tumor development and progression (Bowman et 
al., 2000). Tumorigenesis is a complex process involving a balance of several events, including 
escape from contact-mediated growth arrest, inhibition of apoptosis, angiogenesis, increased pro-
liferation and enhanced migratory and invasive potential (Hahn and Weinberg, 2002). Studies 
have shown that Stat3 could regulate this process through upregulation of anti-apoptosis proteins 
(Bcl-x, Mcl-1), cell cycle regulator (cyclins D1/D2, c-Myc), and angiogenic factors (VEGF) both 
in vitro and in vivo (Sinibaldi et al., 2000; Yu and Jove, 2004).   
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The persistent activation of Stat3 is frequently observed in prostate cancer as well as oth-
er solid tumors. Activated Stat3 is found in both primary human prostate cancer samples and 
prostate cancer cell lines (Dhir et al., 2002; Mora et al., 2002; Ni et al., 2002). Stat3 activation 
depends mainly on deregulation of the tyrosine receptors or associated JAKs. The inhibition of 
Stat3 reduced proliferation and induced apoptosis (Gao et al., 2005). Studies of constitutively 
active Stat3 have shown that overexpression of constitutively active Stat3 leads to anchorage-
independent growth as well as androgen-independent growth in prostatic epithelial cell lines 
(DeMiguel et al., 2002; Huang et al., 2005). Because of its important role in tumorigenesis, Stat3 
has been identified as a new anticancer target. Studies in cell culture and animal models estab-
lished that Stat3 is a promising therapeutic target in a variety of human cancers (Bowman et al., 
2000; Turkson and Jove, 2000). Inhibition of Stat3 signaling has been demonstrated repeatedly 
to cause growth inhibition and apoptosis in tumor cells harboring constitutive active Stat3 (Cat-
lett-Falcone et al., 1999; Lin et al., 2000). 
 
1.7 Matrix metalloproteinase 2/9 (MMP2/9) 
1.7.1 MMP2/9 in cancer progression 
 
The MMPs are a family of highly conserved zinc-dependent endopeptidases, which are 
able to degrade most components of the basement membrane and extracellular matrix. MMPs, 
which are produced by both cancer cells and stromal cells, play a central role in cancer progres-
sion by proteolyzing ECM and allowing tumor cells to escape from the primary site and invade 
the vascular and lymphatic systems (Chambers et al., 2002; Mareel and Leroy, 2003).  Enhanced 
levels of MMPs are now considered to be characteristic of most malignant tumors, and in some 
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carcinomas specific MMPs have been shown to be significant prognostic indicators (Liabakk et 
al., 1996; Murray et al., 1998; Murray et al., 1996; Sier et al., 1996; Talvensaari-Mattila et al., 
1998). Angiogenesis, the formation of new blood vessels, requires proliferation of endothelial 
cells from preexisting blood vessels, breakdown of extracellular matrix and migration of endo-
thelial cells. Because ECM proteolysis is a required process for angiogenesis, MMPs also play a 
critical role during angiogenesis. For example, tumor angiogenesis and tumor growth in MMP-2-
deficient mice is highly reduced (Itoh et al., 1998). In addition, MMPs was shown to be involved 
in regulating tumor growth in both primary and secondary tumors. For example, MMPs were 
shown to degrade insulin-like growth factor binding proteins. The degradation led to the release 
of more IGFs, thus contributing to the growth-regulatory functions of MMPs (Fowlkes et al., 
1995).  
MMPs have also been implicated in EMT, a hallmark of cancer metastasis. Activation of 
growth factors and cleavage of adhesion molecules are the potential mechanisms underlying 
MMP-induced EMT. Among all the MMPs, MMP9 was shown to induce cell migration and in-
vasion in both physiological and pathological processes (Freije et al., 2003; Fridman et al., 2003; 
Himelstein et al., 1994). Secretion of MMP-9 can be triggered by a variety of factors, such as 
cytokines and growth factors. For example, EGF stimulates MMP-9 secretion in breast cancer 
cells (Kondapaka et al., 1997). TGF-β, a potent EMT inducer, also activates MMP-9 in breast 
and prostate cancer cells (Samuel et al., 1992; Sehgal and Thompson, 1999; Welch et al., 1990). 
In addition, overexpression of Snail, a master regulator of EMT, also induced MMP-9 transcrip-
tion expression in MDCK cells, suggesting a role in regulating EMT (Jorda et al., 2005; 
Kondapaka et al., 1997). 
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In prostate cancers, the gelatinases (MMP-2 and MMP-9) have been found to be specifi-
cally associated with prostate cancer metastasis. Increased levels of MMP-2 and MMP-9 in the 
serum and urine have been correlated with metastasis in prostate cancer patients (Gohji et al., 
1998; Moses et al., 1998; Zhang et al., 2004). Secretion of MMP-2 and MMP-9 induce tumor 
angiogenesis in prostate cancer cells (Stearns et al., 1999; Wood et al., 1997). In addition, in-
creased expression of MMP-2 and MMP-9 along with decreased E-cadherin expression at biopsy 
could predict advanced prostate cancer at radical prostatectomy (Kuniyasu et al., 2000; Kuniyasu 
et al., 2003). Moreover, studies showed that the expression of activated MMP-2 was undetecta-
ble in normal prostate, benign PIN, and prostate cancer with low Gleason score. Activated 
MMP-2 was detected in prostate cancers with higher Gleason score and in lymph node metasta-
ses (Stearns and Stearns, 1996). 
 
1.7.2 The regulation of MMP2/9 
 
Transcriptional regulation. MMP-2 and MMP-9 are similar enzymes, but have different 
regulation, glycosylation, proenzyme activation and substrate specificity. MMP-2 is a 72-kDa 
nonglycosylated protein, whereas MMP-9 is a 92-kDa glycosylated protein (Kotra et al., 2002). 
MMP-9 is known to be inducible and under the control of growth factors, chemokines and other 
stimulatory signals (Hipps et al., 1991). There are two important binding sites within MMP-9 
promoter: the Activating Protein-1 (AP-1) site and the Polyoma Enhancer Activator (PEA3) site. 
Cytokines and growth factors that activate MMP-9 expression act through a MAPK pathway, 
such as ERK and JNK. The inducers include EGF, PDGF, HGF, bFGF, TGF-α, TNF-α, IL-1β, 
and IFN-γ. The AP-1 site is located approximately 70 bp upstream of the transcriptional activa-
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tion site and is required for the transcriptional activation of the promoter (Benbow and Brincker-
hoff, 1997; Crawford and Matrisian, 1996). In addition, the PEA3 site binds members of the Ets 
family transcription factors. The PEA3 site was found to be necessary for basal transcription and 
transactivation by cytokines and growth factors. It has been demonstrated that the ETS and AP-1 
binding sites cooperate to enhance transcription, suggesting a synergistic effect between these 
two sites (Crawford and Matrisian, 1996).   
Proenzyme activation.
 
 The gelatinases are synthesized as inactive proenzymes, and need 
to be activated for fully catalytic activity. Therefore, the activation of proMMP-2 or proMMP-9 
is another step in the regulation of MMP activity. The MMPs become catalytically active when 
the propeptide domain is cleaved. The membrane-type1 MMP (MT1-MMP) is the key molecule 
involved in proMMP-2 activation. MT1-MMP and MMP-2 have been shown to be co-localized 
to the plasma membrane of tumor cells (Sato and Seiki, 1996). The activation of proMMP-2 by 
MT1-MMP has been observed in many tumor types, such as lung, brain, and stomach (Nomura 
et al., 1995; Sato and Seiki, 1996; Strongin et al., 1993; Tokuraku et al., 1995; Yamamoto et al., 
1996). Thus, MT1-MMP activates the proMMP-2 and active MMP-2 in turn activates MMP-9.  
1.8 Heparin-binding epidermal growth factor-like growth factor (HB-EGF) 
1.8.1 HB-EGF belongs to EGF-like growth factor family 
 
HB-EGF was first identified as a heparin binding molecule secreted by macrophages (Hi-
gashiyama et al., 1991). It is a 208 amino acid protein of 20-22 kDa in size. Under physiological 
conditions, the N-terminal of HB-EGF, which has more basic amino acids, can interact with neg-
atively charged heparin sulfate proteoglycans both on the cell surface and in the extracellular ma-
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trix. HB-EGF is a member of the EGF family of growth factors. The EGF family of growth fac-
tors is composed of four groups. The first group includes EGF, TGFα, and amphiregulin which 
specifically bind to EGFR (ErbB1). The second group includes HB-EGF, betacellulin and 
epiregulin which bind to both EGFR and ErbB4. The other two groups include neuregulins 1-4 
(Higashiyama et al., 2008). These EGF family ligands exert their function through binding to 
their cognate receptors and activating them. 
HB-EGF gene expression has been detected in many tissues, including the heart, lung, 
brain and skeletal muscle (Abraham et al., 1993). HB-EGF is a potent mitogen and 
chemoattractant for numerous different cell types and is involved in many biological processes, 
such as skin wound healing (Shirakata et al., 2005), angiogenesis (Ongusaha et al., 2004), devel-
opment (Iwamoto and Mekada, 2006; Iwamoto et al.), and cell migration and invasion (Rahman 
et al.). Recently, more and more studies have shown that HB-EGF plays a critical role in cancer 
growth and cancer progression (Higashiyama et al., 2008; Ongusaha et al., 2004; Wang et al., 
2007a; Yagi et al., 2008). 
 
1.8.2 Ectodomain shedding of HB-EGF and EGFR transactivation 
 
HB-EGF is initially synthesized as a membrane-anchored precursor protein-proHB-EGF 
with a short cytoplasmic tail(Massague and Pandiella, 1993). The membrane-anchored HB-EGF 
needs to be cleaved by metalloproteases in order to release the mature soluble form of HB-EGF 
in a process termed ”ectodomain shedding” (Goishi et al., 1995). Regulation of proHB-EGF pro-
cessing is very critical since it controls ligand availability and receptor activation. This step is 
also crucial for cancer development and cancer progression because many proteases which 
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cleave proHB-EGF are disregulated and EGFRs are often constitutively activated in cancers 
(Hynes and Lane, 2005; Mosesson and Yarden, 2004; Murphy, 2008). 
Ectodomain shedding of HB-EGF can be stimulated by various stimuli, such as GPCR 
ligands (Prenzel et al., 1999), growth factors (Murphy, 2008), cytokines and cellular stress 
caused by reactive oxygen and osmotic shock (Kim et al., 2005; Krieg et al., 2004; Tanida et al., 
2004). These shedding stimuli cause release of soluble mature HB-EGF, leading to EGFR trans-
activation and subsequent intracellular signaling activation. Most proteases implicated in 
ectodomain shedding belong to the disintegrin and metalloproteases (ADAMs) family or the ma-
trix metalloproteases (MMPs) family and have been associated with different types of tumors 
(Higashiyama, 2004; Higashiyama and Nanba, 2005). For example, ADAM17, one of the major 
proteases responsible for ectodomain shedding, is found to be upregulated in a range of tumor 
types (Sunnarborg et al., 2002; Yin and Yu, 2009). In addition, MMP2 and MMP9, well docu-
mented proteases which are upregulated in various tumors and involved in cancer metastasis, 
have also been shown to be involved in the ectodomain shedding of HB-EGF (Lucchesi et al., 
2004; Roudabush et al., 2000). 
The ectodomain shedding of pro-HB-EGF produces two fragments: soluble extracellular 
HB-EGF and a c-terminal intracellular fragment. Soluble extracellular HB-EGF exerts its func-
tion in an autocrine or paracrine manner through binding to EGFRs and transactivating them. 
Mice expressing non-cleavable HB-EGF showed severe developmental abnormalities, suggest-
ing that soluble HB-EGF mediates major functions (Yamazaki et al., 2003). Recently, studies 
showed that the HB-EGF c-terminal fragment also has functionality. The HB-EGF c-terminal 
fragment was shown to be able to enter the nucleus to promote S-phase entry by exporting PLZF 
and Bcl6 which are both transcriptional  cell cycle repressors (Nanba et al., 2003). 
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1.8.3 Expression of HB-EGF is high in human cancer 
 
HB-EGF expression is increased in a lot of different cancer types including bladder 
(Kramer et al., 2007), breast (Ito et al., 2001c), colon (Ito et al., 2001a), liver (Ito et al., 2001d), 
ovarian (Tanaka et al., 2005), pancreatic (Ito et al., 2001b) and prostate cancers (Freeman et al., 
1998), compared with normal tissues. Tumors isolated from ovarian cancer patients showed high 
levels of HB-EGF as did ascetic fluid acquired from ovarian cancer patients compared to normal 
samples or patients with benign tumors. Indeed, HB-EGF expression was one or two orders of 
magnitude higher than other EGF family members in ovarian cancer patients (Miyamoto et al., 
2004). In bladder cancer, HB-EGF was also shown to express ten to hundred fold higher than 
other EGFR ligands (Thogersen et al., 2001). These results indicate that HB-EGF might be the 
major ligand responsible for EGFR activation, at least in ovarian and bladder cancers. 
 
1.8.4 HB-EGF promoter regulation 
 
The HB-EGF gene is expressed in a variety of cells and tissues and its expression has 
been shown to be induced by a wide range of signals, such as growth factors, tumor necrosis fac-
tor α, phorbol ester, thrombin and angiotensin II. HB-EGF gene is highly expressed in smooth 
muscle cells and MyoD, AP-1 and Ets-2 have been implicated in stimulating HB-EGF mRNA 
expression through binding to its promoter region during myogenesis, oxidative stress and onco-
genic raf (Chen et al., 1995; McCarthy et al., 1997; Sakai et al., 2001). In addition, regulatory 
macrophages upregulate HB-EGF mRNA transcription through Sp-1 transcription factors (Ed-
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wards et al., 2009). Knockdown of Sp-1 abrogates HB-EGF expression by regulatory macro-
phages.  
 
 
 
1.8.5 HB-EGF is involved in the malignant phenotype of tumors 
 
Since HB-EGF expression is higher in tumors, HB-EGF has been studied for its potential 
role in cancers. It is well demonstrated that HB-EGF can promote cell proliferation and might 
increase the proliferative potential of tumor cells. Overexpression of HB-EGF in normal rat kid-
ney cells or chicken embryo fibroblasts induces oncogenic transformation and anchorage-
independent growth (Fu et al., 1999; Harding et al., 1999). In addition, blocking HB-EGF by an-
ti-HB-EGF antibodies reduced proliferation in human glioblastoma cells (Mishima et al., 1998). 
Overexpression of HB-EGF in human ovarian cancer cells enhanced tumor formation, and 
knockdown of HB-EGF negated tumor formation completely (Miyamoto et al., 2004).  
Soluble HB-EGF has been shown to promote cell migration. Expression of soluble HB-
EGF, but not non-cleavable HB-EGF enhanced MDCK cell motility (Singh et al., 2004). HB-
EGF has also been shown to promote prostate cancer cell migration and invasion (Madarame et 
al., 2003). Recently, studies demonstrated that HB-EGF is involved in EMT in gastric and ovari-
an cancer cells (Yagi et al., 2008; Yin et al.). Treatment with recombinant HB-EGF protein in 
ovarian cancer cells decreased E-cadherin expression but increased Snail expression (Yagi et al., 
2008). In addition, overexpression of non-cleavable HB-EGF increased E-cadherin expression 
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and decreased cell motility in pancreatic cancer cells (Wang et al., 2007a). In summary, HB-EGF 
is involved in cancer cell proliferation, migration and invasion. 
 
 
 
1.8.6 HB-EGF as a therapeutic target 
 
Since HB-EGF is involved in tumor development, migration and invasion, many attempts 
have been made to target HB-EGF as an anti-cancer treatment. CRM197 is a non-toxic mutant of 
diphtheria toxin used as an antitumor drug in clinical trials (Buzzi, 1982; Uchida et al., 1971). 
CRM197 can bind to both soluble HB-EGF and proHB-EGF and then prevent HB-EGF binding 
to EGFRs to stimulate a mitogenic effect (Mitamura et al., 1995). In ovarian cancers, HB-EGF is 
the predominantly expressed EGF ligand. Ovarian cancer tumor growth in xenografted mice was 
signififcanly suppressed by CRM197 (Miyamoto et al., 2004). In addition, CRM197 has shown 
enhanced bioactivity in combination with conventional chemotherapeutic agents (Sanui et al., ; 
Yagi et al., 2009).   
Another strategy is to inhibit HB-EGF ectodomain shedding. Several small molecule in-
hibitors targeting metalloproteases have been developed to inhibit proHB-EGF shedding. Alt-
hough these inhibitors do not specifically inhibit HB-EGF alone, but inhibit all ErbB ligands, 
they did show tumor growth suppression and induction of apoptosis. Therefore, targeting HB-
EGF may be worth trying as a strategy for anticancer treatment. 
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Figure 1.1 
Triple antibody staining (AMACR, p63 and HMWCK). A. Benign gland with basal cell staining 
(brown) and minimal AMACR staining (red). B. HGPIN gland with both basal cell staining 
(brown) and strong AMACR staining (red) in neoplastic cells. C. Adenocarcinoma with no basal 
cell staining but strong AMACR staining (red only).  
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Figure 1.2 
Wnt/β-catenin signaling in cancer.  
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Figure 1.3 
Steps of metastasis.  
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Figure 1.4 
Secondary structure analysis of LIV-1.  
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Figure 1.5 
EGFR signaling pathways. 
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Figure 1.6 
Ras/Raf/MEK/ERK signaling in tumors.  
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Figure 1.7 
Multiple ways lead to activate Stat3.  
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2 LIV-1 PROMOTES HUMAN PROSTATE CANCER EPITHELIAL-TO-
MESENCHYMAL TRANSITION AND SKELETAL AND SOFT TISSUE METAS-
TASES  
2.1 Abstract 
 
Metal transporter LIV-1 is an effecter molecule downstream from soluble growth factors, 
promoting epithelial to mesenchymal transition (EMT).  We examined the role of LIV-1 in pro-
moting prostate cancer progression and metastasis using the human prostate cancer ARCaP EMT 
model.  Upon overexpressing LIV-1 in ARCaPE cells (ARCaP cells expressing epithelial pheno-
type), we observed a permanent transition of ARCaPE to mesenchymal phenotype, with 
mesenchymal stromal morphology and expression of stromal markers N-cadherin and Snail, but 
loss of epithelial E-cadherin.  Importantly, LIV-1-overexpressing ARCaPE cells exhibited in-
creased migratory and invasive potential in vitro and enhanced subcutaneous tumor formation in 
vivo, while intracardiac inoculation resulted in marked bone and soft tissue metastasis in athymic 
mice.  In addition, we found that LIV-1 level in clinical human prostate cancer specimens is ab-
normally elevated, with the highest expression seen in bone metastatic tumor.  Our study sup-
ports the concept that LIV-1 is an important downstream effecter to soluble growth factors, pro-
moting EMT and prostate cancer growth and metastasis.  LIV-1 can be considered as a novel 
target for future therapeutic development. 
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2.2 Introduction 
 
Epithelial to mesenchymal transition (EMT) is a common feature of cancer where tumor 
cells acquire increased growth, survival, migratory, invasive and metastatic behaviors as the dis-
ease progresses.  This is probably due to a reawakening of the biologic functions of embryonic 
tissues during development and normal tissue repair upon wound healing (Acloque et al., 2009; 
Dvorak, 1986; Micalizzi and Ford, 2009).  Through EMT, embryonic cells gain invasive and mi-
gratory potential for organogenesis and cytodifferentiation.  Recapitulating these embryonic pro-
cesses, pathologic EMT is known to promote fibrosis, inflammation, and cancer cell migration, 
invasion and metastasis (Acloque et al., 2009; Thiery et al., 2009).  EMT in solid tumors includ-
ing prostate cancer is considered as a key molecular event in cancer progression (Whitbread et al., 
2006; Xu et al., 2006; Zhau et al., 2008). 
At the cellular level, EMT precedes the loss of epithelial cellular polarity, causing de-
tachment of epithelial cells from their primary site and increasing their migratory and invasive 
properties.  These changes ultimately accelerate the dissemination of cancer cells to distant or-
gans.  In both normal development (e.g. metazoan gastrulation and neural crest development) 
and neoplastic progression, epithelial cells reach secondary sites and re-establish cell polarity, 
with increased cell adhesion and interaction with resident cells.  This phase of the process is in-
dicative of a reversal of EMT, or mesenchymal to epithelial transition (MET) (Duband et al., 
1995; Hay and Zuk, 1995).  Due to the promotion of interaction with resident cells, cancer cell 
MET may lead to cancer-associated bone turnover and tumor angiogenesis, with devastating ef-
fects in cancer-bearing hosts (Baum et al., 2008; Kim and Salgia, 2009).  The cancer-host inter-
action enhances regenerating ability (or stemness) of cancer cells thus promoting tumor growth, 
survival, and leading to potential secondary cancer metastases (Hugo et al., 2007; Spaderna et al., 
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2007; Thompson and Williams, 2008).  Delineating the molecular mechanism of EMT and MET 
is critical to developing effective therapies for prostate cancer progression and bone metastasis. 
LIV-1 is a candidate regulator of EMT and MET processes.  As the prototype of the LIV-
1 subfamily of ZIP metal transporters (Taylor, 2000; Taylor et al., 2003), it represents a group of 
proteins that are similar to ZIP transporters in secondary structure and in their ability to transport 
metal ions.  Originally identified in the breast cancer cell line ZR-75-1 as an estrogen-regulated 
gene (Manning et al., 1988), LIV-1 has been associated with ERα status in breast tumor biopsies 
(Dressman et al., 2001; Tozlu et al., 2006), and with the spread of breast cancer to the regional 
lymph nodes (Manning et al., 1994).  In cervical cancer, expression of LIV-1 was shown to be 
higher in tumor cells than in normal tissues (Zhao et al., 2007a).  RNAi-mediated suppression of 
LIV-1 in HeLa cells significantly inhibited cell proliferation and colony formation, leading to 
reduced migratory and invasive ability (Zhao et al., 2007b).  In zebrafish, LIV-1 was reported to 
be essential for the nuclear localization of Snail, a master transcription factor stimulating EMT, 
causing migration of the gastrula organizing cells (Yamashita et al., 2004).  Additionally, LIV-1 
was shown to cooperate with Snail by binding to promoter of the epithelial marker E-cadherin 
gene to repress its transcription (Cano et al., 2000).  It appears that LIV-1 is an obligatory co-
factor regulating EMT-associated genes. 
Potential biologic functions and the diagnostic and prognostic values of LIV-1 in human 
prostate cancer have not been investigated.  Since zinc plays important roles in the maintenance 
of prostate epithelial cell homeostasis (Bataineh et al., 2002), and Snail is an master transcription 
factor controlling EMT in prostate cancer cells (Barrallo-Gimeno and Nieto, 2005; Batlle et al., 
2000; Odero-Marah et al., 2008), LIV-1 may be an active participant in the promotion of EMT 
during prostate cancer progression and bone metastasis.  In this study, we determined the level of 
53 
LIV-1 in human prostate cancer cell lines and clinical tissue specimens to define the relationship 
between LIV-1 expression and human prostate cancer progression and metastasis.  The ARCaP 
human prostate cancer progression cell model was used to evaluate the role of LIV-1 in the in-
duction of EMT.  This study found that LIV-1 promotes prostate cancer cell EMT, leading to 
both bone and soft tissue metastases.  In addition, the results from this study demonstrate that 
molecular suppression of LIV-1 could be a therapeutic strategy to inhibit prostate tumor cell 
EMT and prostate cancer bone metastasis. 
 
2.3  Material and Methods 
2.3.1 Ethics statement.  
 
All animal work had been conducted according to relevant national and international 
guidelines, and was approved by the Institutional Animal Care and Use Committee (IACUC) of 
Emory University School of Medicine (Permit number 254-2008). 
 
2.3.2 Cell lines and cell culture.  
  
Human prostate cancer ARCaPE and ARCaPM cells were established in our laboratory 
(Xu et al., 2006).  The cells were cultured in T-medium (Invitrogen, Carlsbad, CA) supplement-
ed with 5% fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville, GA).  Human embry-
onic kidney HEK293 cells were obtained from American Type Culture Collection (Manassas, 
VA) and cultured in DMEM (Invitrogen) supplemented with 10% FBS.  RPMI-1640 was pur-
54 
chased from Invitrogen (Carlsbad, CA).  All the culture media were supplemented with penicillin 
(100 U/ml) and streptomycin (100 μg/ml).  Cell cultures were maintained at 37°C in a humidi-
fied atmosphere supplemented with 5% CO2. 
 
2.3.3 Antibodies and reagents.  
  
Polyclonal rabbit antibody against LIV-1 was generated in our laboratory.  Rabbits were 
immunized by standard immunization protocol with conjugated peptide KLH-
CPDHDSDSSGKDPRNS, corresponding to residues 146-161 of the LIV-1 protein (GenBank 
accession number NM_012319).  Blood was taken 2 weeks after the fourth boost and IgG were 
purified and tested for specific immune reactivity.  Polyclonal antibody to E-cadherin (E-cad), 
and monoclonal antibody to vimentin antibody were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA).  Monoclonal antibody to N-cadherin (N-cad) was from BD Transduction La-
boratories (San Diego, CA).  Monoclonal antibody to β-actin was from Sigma-Aldrich (St. Louis, 
MO). 
Growth factors of IGF-1 and TGF-β1 were purchased from Diagnostic Systems Labora-
tories (Webster, TX).  EGF was from R&D Systems (Minneapolis, MN).   
 
 
 
2.3.4 Transfection.   
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Full-length coding region for human LIV-1 cDNA was cloned and confirmed by DNA 
sequencing.  The cDNA was then cloned downstream from a cytomegalovirus early promoter in 
the mammalian expression vector pcDNA3.1/V5-His (Invitrogen).  HEK293 and ARCaPE cells 
were seeded at 3 × 105 cells per well in 6-well plates 24 hours before transfection.  The cells 
were transfected with 4 μg of the LIV-1 expression construct using 8 μl Lipofectamine 2000 
(Invitrogen).  To isolate clones stably overexpressing the LIV-1, transfected ARCaPE cells were 
treated with G418 (600 μg/ml) 2 days after the transfection.  Four individual clones overexpress-
ing LIV-1 protein (LIV#8, #12, #14 and #17) and two clones transfected with control vector 
(con1 and con2) were used for the studies. 
 
2.3.5 siRNA knockdown.  
  
LIV-1 siRNA was purchased from Invitrogen.  ARCaPM cells were seeded at 3 × 105 
cells per well in 6-well plates for 24 hrs.  The cells were transfected with 2.5 μl of 20 μM LIV-1 
siRNA or equal amount of universal control siRNA, using 8 μl Lipofectamine 2000 per well.  
Cells were harvested and assayed 48 hours after transfection. 
 
 
 
2.3.6 RNA extraction. 
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The RNeasy Mini kit (Qiagen, Valencia, CA) was used to extract total RNA from cells. 
350 μl of buffer RLT with 3.5 μl of β-mercaptoethanol was added to cells grown in a 6-well plate. 
350 μl of 70% ethanol was added to each sample, mixed well and transferred to an RNeasy spin 
column. Each sample was centrifuged for 30 seconds at 10,000 rpm. Each column was washed 
with 700 μl of RW1, and centriguged for 30 seconds at 10,000 rpm. Then each column was 
washed with 500 μl of RPE twice, and centriguged for 30 seconds at 10,000 rpm. Next, each col-
umn was centrifuged for additional 30 seconds at 10,000 rpm and added 30 μl of RNAse-free 
water to elute RNA. RNA samples were stored at -80 ̊C until use. 
 
2.3.7 Semiquantitative expression analysis with reverse transcription-polymerase chain 
reaction (RT-PCR).   
 
Total RNA was isolated from cultured cells using the RNeasy Mini kit (Qiagen, Valencia, 
CA).  From each sample, equal amount of RNA (2 μg) was used in first–strand cDNA synthesis 
reaction with the Superscript First-Strand cDNA Synthesis kit (Invitrogen).  Basically, 2 μg of 
total RNA is combined with 1 μl of 50 ng random hexamer or 50μM oligo dT primer and DEPC-
treated water to 6 μl, incubate for 5 minutes at 65 ̊C, and place on ice for additional 5 minutes. 
Next, 2 μl of 10 RT buffer, 4 μl of 25 mM MgCl2, 2 μl of 0.1M DTT, 1 μl of RNAseOUT, and 1 
μl of SuperScript III RT was added to each sample. The samples are incubated at 25 ̊C for 10 
minutes, followed by 50 ̊C for 50 minutes, 85 ̊ C for 5 minutes, and chilled on ice. Equal volume 
of cDNA (3 μl) from each reaction was used for PCR analysis using gene-specific oligonucleo-
tide primer pairs: 5’-GCAATGGCGAGGAAGTTATCT-3’ and 5’-
CTATTGTCTCTAGAAAGTGAG-3’ for LIV-1; 5’-TGCCCAGAAAATGAAAAAGG-3’ and 
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5’-GTGTATGTGGCAATGCGTTC-3’ for E-cad; ; 5’-CCATCACTCGGCTTAATGGT-3’ and 
5’-GATGATGATGCAGAGCAGGA-3’ for N-cad; 5’-CGAAAGGCCTTCAACTGCAAAT-3’ 
and 5’-ACTGGTACTTCTTGACATCTG-3’ for Snail; and 5’-TTAGCACCCCTGGCCAAGG-3’ 
and 5’-CTTACTCCTTGGAGGCCATG-3’ for GAPDH.  The reactions were initiated with a 4-
minute incubation at 94°C, followed by 30 cycles at 94°C for 30 seconds, 55°C for 30 seconds, 
and 72°C for 1 minute.  The reaction was completed with a 7-minute extension at 70°C for 7 
minutes.  PCR products were visualized after electrophoresis through a 1.2% agarose gel and 
stained by ethidium bromide (0.5 μg/ml). 
 
2.3.8 Western blotting.  
  
Cells at 80% confluence were lysed in a whole-cell lysis buffer as previously reported 
(Wang et al., 2007b).  The lysates were incubated on ice for 30 minutes and centrifuged at 
10,000 rpm at 4°C for 10 minutes.  From each sample, 35 μg protein in the supernatant was re-
solved by SDS-PAGE and blotted onto a nitrocellulose membrane (BioRad, Hercules, CA), 
which was blocked in 5% skim milk in PBST (137 mM NaCl, 12 mM phosphate, 2.7 mM KCl, 
and 0.1% Tween 20) at room temperature for 20 minutes; and incubated with primary antibody 
at 4°C overnight.  The membranes were then washed three times in PBST, and incubated with 
horseradish peroxidase-conjugated secondary antibody for 1 hour at room temperature.  After 
five washings in PBST, specific signal was detected by incubating the membrane with ECL rea-
gent (Amersham-Pharmacia Biotech, Piscataway, NJ). Exposure time might vary depending on 
the intensity of signal. After exposure, the membrane was stripped by stripping buffer (Pierce) 
and reprobed with different primary antibodies. 
58 
 
2.3.9 Scratch wound healing assay. 
 
ARCaPM cells transfected transiently with LIV-1 siRNA or universal siRNA control were 
used to determined migratory behavior. Gently and slowly scratch the cells with a 10 μl pipette 
tip across the center of the well 48 hours after transfection. After scratching, gently wash the well 
twice with medium to remove the detached cells. Replenish the well with fresh medium. Photos 
were taken after scratch at 0 and 48 hrs later. Multiple views of each well were documented, and 
three independent experiments were performed. 
 
2.3.10 Trans-well migration and invasion assays. 
 
To perform a trans-well migration assay, 2.5 × 104 cells in the top chamber of 24-well 
trans-well plates of 8 µm pore size (BD Biosciences) were incubated for 16 hours in complete 
medium that was added to the bottom chamber.  Cells were then fixed with formalin and stained 
with 0.5% crystal violet.  The non-migrated cells inside the chamber were removed by swabbing.  
Crystal violet of the migrating cells was solubilized into the Sorenson’s buffer (0.1 M sodium 
citrate and 50% ethanol, pH 4.2) and was measured for absorbance at OD590.  Invasion assay was 
performed using BD BioCoat Matrigel invasion chambers (BD Biosciences; 8-µm pore size).  
The same procedures described above were used, except the filters were pre-coated with 100 μl 
Matrigel at a 1 : 4 dilution in RPMI-1640. 
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2.3.11 Assessment of tumorigenic and metastatic potentials.   
 
The functional roles of LIV-1 in prostate tumor formation and metastasis were assessed 
as we have reported previously (Thalmann et al., 2000).  To assess local tumor growth, 4-weeks 
old athymic male mice (Ncr-nu/nu, National Cancer Institute, Frederick, MD) were inoculated 
subcutaneously with ARCaPE cells (1 × 106 in 50 μl PBS) stably transduced with LIV-1.  Tumor 
dimension was measured with a caliper at days 23, 32, 43, and 50 after injection, and tumor vol-
ume was calculated as length × width × height × 0.5236 (Janik et al., 1975).  To assess cancer 
metastases, athymic male mice were inoculated intracardiacally with ARCaPE cells (2 × 106 in 
100 μl PBS) stably transduced with LIV-1 to the left ventricles.  Animals were observed for 4 
months for development of metastatic lesions.  Bone metastases were recorded by X-ray radiog-
raphy and soft tissue metastases was confirmed by histopathology. 
 
2.3.12 Immunohistochemistry (IHC) of tissue microarray (TMA). 
   
The normal and diseased prostate tissues analyzed were from: 1) One custom-made TMA 
with normal prostate tissues from 4 healthy men; matched cancer, benign, and PIN tissues from 
12 prostate cancer cases; matched benign and cancer tissues from 11 cases; matched PIN and 
cancer from 1 case; benign prostatic hyperplasia (BPH) from 2 cases; and prostate cancer bony 
metastasis from 3 prostate cancer cases.  2) One custom-made TMA consists 47 bone metastasis 
tissues from 11 prostate cancer patients; and 3) Four TMAs each containing 66 cases of prostate 
cancer and benign prostate disorders (US Biomax. Rockville, MD). 
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The IHC protocol for evaluating gene expression has been reported (Wang et al., 2007b).  
Briefly, specimens were deparaffinized, rehydrated and subjected to antigen retrieval.  After en-
dogenous peroxidase block, the specimens were incubated with primary antibody at 4˚C over-
night, followed by a 30-minute incubation with DakoCytomation EnVision+ HRP reagent.  Sig-
nals were detected by adding diaminobenzidine as chromogen and counterstained by 
hematoxylin.  Pre-immunization rabbit serum was served as negative controls.  IHC staining was 
scored by two investigators independently based on four staining intensities from 0 to +++ as 
previously reported (Wang et al., 2007b). 
2.3.13 Statistical analysis. 
To analyze the potential association of LIV-1 protein expression and prostate cancer pro-
gression from normal/benign, prostatic intraepithelial neoplasia (PIN), localized primary cancer, 
to bone metastasis, LIV-1 expression level was divided into two categories: staining intensity of 
high (3) vs. medium to null (2 to 0, respectively).    Kruskal Wallis non-parametric test was used 
to determine the equality of population medians among prostate cancer progressions of nor-
mal/benign, PIN, primary cancer, and bone metastasis.  This test is equivalent to the parametric 
ANOVA test used when there are more than two groups were compared.  Mann-Whitney non-
parametric test was applied to determine the equality of population medians between two cancer 
progressions, 1) bone metastasis vs. localized cancer; and 2) bone metastasis vs. benign, PIN, 
and primary localized cancer.  This test is equivalent to the parametric t-test used when there are 
only two groups compared.    Logistic regression was used to model the relationship between 
binary Gleason scores which were divided into binary variables of well differentiated (GI<=6) vs. 
moderate to poorly differentiated (GI>=7) prostate cancer.  SAS and Minitab were used in this 
analysis.  
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2.4 Results 
 
The human prostate cancer ARCaP cells established in our laboratory (Xu et al., 2006) 
can be readily promoted to undergo EMT in response to soluble factors and matrix proteins pre-
sent in the milieu of tumor microenvironment (Graham et al., 2008; Josson et al., ; Odero-Marah 
et al., 2008; Zhau et al., 2008).  To elucidate the molecular mechanism regulating EMT, the epi-
thelial ARCaPE was analyzed for differential gene expression, in response to soluble factors, in 
comparison to its ARCaPM counterpart, which displayed a mesenchymal stromal phenotype.  
LIV-1 was one of the differentially expressed genes identified (Zhau et al., 2008).  In the current 
study, we investigated the role of LIV-1 in regulating EMT in ARCaP cells to assess the possible 
mechanism of LIV-1 action in the promotion of prostate cancer bone and soft tissue metastases. 
 
2.4.1 LIV-1 was involved in promoting EMT in ARCaP cell model. 
 
We have previously reported that ARCaPE cells underwent EMT when treated with solu-
ble factors including IGF-1, EGF, TGF-β1 and β-2 microglobulin (β-2M) (Graham et al., 2008; 
Josson et al., ; Odero-Marah et al., 2008; Zhau et al., 2008).  In the present study, when ARCaPE 
cells were treated with either TGF-β1 or IGF-1, an induction of LIV-1 expression was detected 
by both RT-PCR and Western blotting analyses (Figure 2.1).  When different concentrations of 
IGF-1 were added to the induction medium, the responsiveness of LIV-1 expression was found 
to be dose-dependent (Figure 2.1).  IGF-1-induced LIV-1 expression in ARCaPE cells occurred 
concomitantly with a switch of cell morphology and gene expression toward mesenchymal phe-
notype, i.e., the loss of tightly adhesive polarized epithelial morphology to become loosely dis-
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persed fibroblastic cells with increased expression of N-cad and vimentin but decreased expres-
sion of E-cad, a hallmark retained by polarized epithelial cells (Figure 2.2).  An activated LIV-1 
expression seemed to occur concurrently with the transition of ARCaPE to ARCaPM, an ARCaP 
mesenchymal variant (Xu et al., 2006). 
To define the role of LIV-1 in mediating EMT, we transiently reduced LIV-1 level in the 
mesenchymal-like ARCaPM cells by siRNA knockdown.  ARCaPM cells treated with specific 
LIV-1 siRNA showed markedly reduced LIV-1 transcripts (Figure 2.3).  Importantly, the treated 
cells showed decreased expression of mesenchymal markers N-cad and Snail, but increased ex-
pression of the E-cad gene in both RT-PCR and Western blotting analyses (Figure 2.3).  In addi-
tion, ARCaPM cells treated with specific LIV-1 siRNA exhibited much reduced migratory and 
invasive ability in scratch wound-healing (Figure 2.4) and transwell invasion assays (Figure 2.5). 
These results suggested that LIV-1 expression is associated with EMT and decreased LIV-1 ex-
pression lead to mesenchymal to epithelial transition (MET), a reversal of the EMT.  The pres-
ence of LIV-1 appeared to be required for the maintenance of a mesenchymal phenotype. 
We next examined whether an elevated LIV-1 in the epithelial-like ARCaPE cells would 
be sufficient to initiate EMT, assessed by molecular analyses.  Following transient transfection 
with a LIV-1 expression construct, ARCaPE cells were examined by both RT-PCR and western 
blotting assays for the expression of EMT-associated markers.  The transfected ARCaPE cells 
displayed markedly increased LIV-1 expression (Figure 2.6), accompanied by increased N-cad 
and Snail but a decreased E-cad expression.  These expressional changes were in agreement with 
those seen in growth factor-elicited EMT (Figure 2.2).  Results from LIV-1 siRNA knockdown 
and LIV-1 overexpression studies in respective ARCaPM and ARCaPE cells suggested that LIV-1 
could be a key regulator of EMT in human prostate cancer cells. 
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2.4.2 Production and characterization of polyclonal antibodies to human LIV-1. 
 
To evaluate if LIV-1 expression is associated with clinical progression of human prostate 
cancer, we raised polyclonal antibodies by immunizing rabbits with a KLH-conjugated LIV-1 
peptide.  Specificity of LIV-1 antibodies was confirmed by Western blotting of the whole-cell 
extracts from cells overexpressing exogenous LIV-1.  From the HEK293 cells transiently trans-
fected with LIV-1, we observed a single immune-reactive LIV-1 protein, at 110 kDa (Figure 2.7).  
Since the calculated molecular weight of LIV-1 protein is 90 kDa (Taylor et al., 2003), the dif-
ferential 20 kDa between the detected and the predicted sizes was likely attributed to N-linked 
glycosylation of the LIV-1 protein, as previously reported (Taylor et al., 2003).  Importantly, the 
signal detected by the LIV-1 antibodies was abolished when the antibodies were pre-adsorbed 
with the LIV-1 peptide used in immunization.  In addition, increased signal intensity was detect-
ed in ARCaPE cells transiently transfected with the LIV-1 expression construct, while a reduction 
of the signal was seen in ARCaPM cells treated with a transient LIV-1 knockdown vector in both 
Western blotting and IHC assays (Figure 2.7&2.8).  These results indicated that the LIV-1 anti-
bodies produced could detect specifically LIV-1 protein, which was modified in the cell lines 
tested. 
 
2.4.3 Stable LIV-1 overexpression induced EMT in ARCaPE cells. 
 
Following transient knockdown of LIV-1 in ARCaPM cells, an expected reversal of the 
mesenchymal fibroblastic cell shape to epithelial morphology was observed.  These morphologic 
switches were readily detectable by gene expression changes (Figure 2.3).  In contrast, however, 
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transiently overexpressing LIV-1 in ARCaPE cells did not bring forth conspicuous mesenchymal 
fibroblastic morphology, despite of concerted expressional changes indicative of EMT (Figure 
2.6).  We suspected that the lack of morphologic changes may be attributable to the nature of the 
transient transfection.  Accordingly, stable ARCaPE clones were established to evaluate whether 
LIV-1 is a critical regulator associated with morphologic as well as expressional and behavior-
ally transition from an epithelial to a mesenchymal phenotype. 
We isolated 4 ARCaPE clones (LIV#8, 12, 14 and 17) stably expressing high levels of 
LIV-1 protein, as detected by Western blotting (Figure 2.9).  Two control clones (con1 and con2) 
were also isolated from transfection with the control vector.  The ones overexpressing LIV-1 
showed typical EMT-like expressional changes, with decreased E-cad expression but increased 
N-cad and Snail expressions (Figure 2.9).  Significantly, all the clones showed markedly changed 
cellular morphology: instead of the small cell size with cobblestone-like shape with tightly ar-
ranged intercellular contact typical of the epithelial cell-like ARCaPE, all the four clones adapted 
remarkably altered morphology displayed a loss of intercellular contact, exhibiting typical spin-
dle-shaped mesenchymal cell morphology (Figure 2.10).  The morphologic transition was per-
manent and irreversible, persisting after more than 30 passages in continuous culture, while the 
two vector-transfected clones remained epithelial cell-like.  It seems that stable LIV-1 overex-
pression could bring forth both morphologic and biochemical EMT transition.  LIV-1 is thus a 
potent promoter of EMT in ARCaPE cells. 
The effects of LIV-1 on behavioral changes were assessed for its promotion of cell mi-
gration and invasion as assessed by Boyden chamber assays.  While the control neo transfected 
ARCaPE clones showed similar migration and invasion capabilities closely mimic those of the 
parental ARCaPE cells, repeated assays revealed LIV-1 overexpression conferred significantly 
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increased migratory capability (Figure 2.11) and invasive potential to penetrate extracellular ma-
trices (Figures 2.12).  Taken together, these data support the notion that increased LIV-1 levels 
promote prostate cancer cells to gain motility and invasive behaviors. 
 
2.4.4 LIV-1 overexpression promoted in vivo prostate tumor formation and distant me-
tastases. 
 
We examined the role of LIV-1 stably expressed in ARCAPE cells in modulating their 
subsequent tumorigenic and metastatic behaviors in mice.   We compared local and distant meta-
static growth of ARCaPE tumors by the use of subcutaneous and intracardiac tumor cell inocula-
tion protocols as described previously (Thalmann et al., 2000; Xu et al., 2006). 
Following subcutaneous implantation, LIV-1 overexpressing clones induced similar inci-
dence of tumor formation as the vector-transfected controls, each group having 6 tumors from a 
total of 8 inoculations.  Nonetheless, LIV-1-overexpressing clones formed significantly larger 
tumors than the control clones when the tumors were measured at 43 and 50 days after inocula-
tion (Figure 2.13).  Due to the large tumor burden in the LIV-1 transfected experimental group, 
these studies were terminated at 50 days.  At this time, the average tumor size of LIV-1-
overexpressing clones was 3 - 5 times larger than that of the control clones, with no evidence of 
distant metastases. 
We then used intracardial inoculation to evaluate the metastatic fate of LIV-1 overex-
pressing ARCaPE cells.  Four months after intracardiac administration, the mice inoculated with 
LIV-1 overexpressing ARCaPE clones presented with significantly elevated incidence of tumors 
at multiple organ sites, including the bone and soft tissues of lymph nodes, adrenal glands, and 
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the lung, compared to vector-transfected controls (Table 1&Figure 2.14).  Among the seven ani-
mals inoculated with LIV-1-overexpressing ARCaPE clone 8, two were found to have multiple 
bone metastases, both in tibial, mandibular, and spinal bones (Figure 2.15A), while another four 
mice were found to harbor soft tissue tumors of the adrenal glands and the lung (Figure 2.15B).  
All the tumors were confirmed by histopathologic analysis.  In a parallel study, five of the nine 
animals inoculated with LIV-1-overexpressing ARCaPE clone 14 were found to bear bone metas-
tasis.  In sharp contrast, intracardiac inoculation of vector-transfected controls did not produce 
any detectable metastases in bone or soft tissues (Table 1).  This series of assays demonstrated 
that by increasing migratory and invasive behaviors of prostate cancer cells, LIV-1 promoted 
metastatic growth of prostate cancer cells to the bone and the soft tissues. 
 
2.4.5 Enhanced LIV-1 expression in clinical prostate cancer specimens. 
 
In order to examine the correlation of LIV-1 expression and cancer malignancy, we first 
access LIV-1 expression in different prostate cancer cell lines. We choose isogenic LNCaP series 
(LNCaP, C4-2 and C4-2B) and ARCaP series (ARCaPE, ARCaPM and ARCaPM2) cell lines. 
Both series are from low potential of metastasis to high potential of metastasis, with C4-2, C4-
2B, ARCaPM and ARCaPM2 specifically metastasize to bone.  We found that LIV-1 expression 
correlated with the metastatic potential of these isogenic cell models.  LIV-1 expression is higher 
in the bone metastatic cell lines than those of the non- or low-metastatic cells such as LNCaP and 
ARCaPE (Figure 2.16).  
Based on the findings in ARCaP cells where LIV-1 was shown to induce EMT and pros-
tate cancer local growth and distant metastases and LIV-1 expression in different cancer cell 
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lines, we seek to demonstrate the clinical relevance of these findings by performing a series of 
IHC assays.  A LIV-1 polyclonal antibody established by our laboratory was used to detect LIV-
1 status in clinical specimens on two custom-made TMAs of normal, benign/PIN, localized and 
bone metastatic prostate cancers and four commercial TMAs of benign and prostate cancer spec-
imens.  These TMAs represented a total of 344 prostate specimens including bone metastasis 
specimens from 14 patients. Results from Kruskal Wallis non-parametric test showed remarkable 
positive correlation of LIV-1 expression with disease progression from normal, benign, PIN, 
primary to bone metastasis (P < 0.001).  Figure 2.17 showed the representative IHC images of 
increased LIV-1 expression in human prostate specimens from benign to bone metastasis. Signif-
icant differences were also found when LIV-1 expression was subjected to Mann-Whitney non-
parametric test between either bone metastasis and localized cancer (p=0.002); or bone metasta-
sis and normal/ benign, PIN, primary cancer and metastasis (p=0.001) (Figure 2.18). There was, 
however, no positive correlation between LIV-1 expression in well-differentiated (GI<=6) and 
moderate to poorly-differentiated (GI>=7) prostate cancers by Logistic regression test.  
In summary, our study demonstrated that abnormally enhanced LIV-1 confers the ability 
for prostate cancer cells to migrate and invade in vitro and metastasize to the bone and soft tis-
sues in experimental mouse model. ARCaP cell model of EMT allows us to gain additional in-
sight linking LIV-1, a zinc transporter, to cancer cell growth and survival through the induction 
of EMT. In addition, LIV-1 expression was found to be correlated with cancer progression in 
clinical specimens. Thus, LIV-1 could be a new therapeutic target for prostate cancer progression 
and metastasis. 
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Table 1.  LIV-1 promotes prostate cancer cell metastasis.* 
Clones Incidence of metastasis Sites of metastasis 
con1 0/6 N/A 
con2 0/6 N/A 
LIV#8 6/7 (86%) 2, adrenal gland 
2, lung 
1, leg bone 
1, jaw and spine 
LIV#14 5/9 (56%) 2, leg bone 
1, iliac bone 
1, femur 
1, zygomatic and spine 
 
* LIV-1-overexpression clones (LIV#8 and LIV#14) and vector-transfected clones (con1 and 
con2) were intracardially inoculated to athymic mice.  Incidence and sites of metastasis were fol-
lowed up to 4 months by necropsy and histopathologic confirmation. 
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                                                                  Figure 2.1 
LIV-1 is a mediator in ARCaPE cell EMT.  The role of LIV-1 was assessed by its changed 
expression during EMT.  A, ARCaPE cells were treated for 48 hours with growth factors to 
induce EMT.  RT-PCR and Western blotting were used to show increased LIV-1 expression (left 
panel), and dose responsiveness of the expression (right panel).  
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Figure 2.2 
Treatment of growth factors induced EMT. Western blotting was used to confirm EMT-like ex-
pressional changes in the treated ARCaPE cells. 
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Figure 2.3 
Knockdown of LIV-1 induced MET. The mesenchymal cell-like ARCaPM cells were subjected 
to siRNA knockdown for LIV-1 expression for 48 hours.  RT-PCR and Western blotting were 
used to detect expressional changes reflecting reverse of EMT in the treated cells.   
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Figure 2.4 
Knockdown of LIV-1 reduced migratory capability. Scratch wound healing was used to deter-
mine the migratory and invasive behavior in the siRNA treated ARCaPM cells. 
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Figure 2.5 
Knockdown of LIV-1 suppressed invasive ability. Transwell invasion assays were used to de-
termine the migratory and invasive behavior in the siRNA treated ARCaPM cells. * indicates sta-
tistical significance compared to the con1 control clone (P < 0.05). 
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Figure 2.6 
Transient overexpression of LIV-1 induced EMT. ARCaPE cells were transfected with LIV-1 
expression construct.  RT-PCR and western blotting were performed 48 hours after the transfec-
tion to detect expressional changes reflecting EMT-like events.  GAPDH served as an internal 
control for RT-PCR reactions, and β-actin was used as a loading control in Western blotting.  
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Figure 2.7 
The produced antibodies to LIV-1 were subjected to validation for specificity.  A, HEK293 cells 
transiently transfected with the LIV-1 expression construct were subjected to Western blotting 
analysis with the antibodies to LIV-1 (upper panel).  Antibody specificity was determined by 
pre-absorbing the antibody with the immunizing peptide (middle panel).  B, ARCaPE cells were 
transiently transfected with the LIV-1 expression construct to overexpress LIV-1 and ARCaPM 
cells with the specific siRNA to suppress LIV-1 expression.  In the upper 2 panels, Western blot-
ting was performed 48 hours later with the antibodies to LIV-1.  In the lower 2 panels, these cells 
were examined by RT-PCR to confirm the LIV-1 expression.  β-actin was used as control in 
Western blotting and GAPDH was used as control for RT-PCR analysis. 
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Figure 2.8 
Specificity of LIV-1 antibody was comfirmed by IHC. IHC was conducted to further confirm 
LIV-1 Ab specificity in ARCaPE cells transfected with the LIV-1 expression construct and 
ARCaPM cells transfected with the specific siRNA.  
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Figure 2.9 
LIV-1 overexpression induced EMT.  ARCaPE clones overexpressing LIV-1 displayed EMT-like 
changes in gene expression.  All four LIV-1 overexpressing ARCaPE clones showed EMT-like 
expressional changes as detected by Western blotting, while the two vector control clones (1 and 
2) retained an epithelial cell-like expression profile. 
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Figure 2.10 
ARCaPE clones overexpressing LIV-1 displayed EMT-like changes in cellular morphology. Cel-
lular morphology of the LIV-1 overexpressing cells showed marked changes from the control 
clones (200 ×). 
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Figure 2.11 
Overexpression of LIV-1 exhibited increased migratory ability. LIV-1 overexpressing cells 
(LIV#8 and LIV#14 were compared with vector control clones 1 and 2 and parental ARCaPE and 
ARCaPM cells for altered migratory capability in transwell assays.  Each result is the mean ± 
standard deviation of a triplicate assay. * indicates statistical significance compared to the con1 
control clone (P < 0.05). 
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Figure 2.12 
Overexpression of LIV-1 exhibited enhanced invasive ability. LIV-1 overexpressing cells 
(LIV#8 and LIV#14 were compared with vector control clones 1 and 2 and parental ARCaPE and 
ARCaPM cells for invasiveness in transwell invasion assays.  Each result is the mean ± standard 
deviation of a triplicate assay.  * indicates statistical significance compared to the con1 control 
clone (P < 0.05). 
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Figure 2.13 
LIV-1 overexpression promoted subcutaneous tumor growth.  Upon subcutaneous inoculation, 
the two ARCaPE clones overexpressing LIV-1 (LIV8 and LIV14) were compared with vector 
control clones (con1 and con2) for tumor formation in athymic mice.  Growth of the tumors at 
day 23, 32, 43, and 50 is shown.  Each result represents the mean ± standard deviation of six tu-
mors.  An asterisk indicates statistical significance compared to the con1 control clone (P < 0.05). 
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Figure 2.14 
LIV-1 overexpression promoted cancer bone and soft tissue metastasis.  Upon intracardiac in-
oculation, ARCaPE clones overexpressing LIV-1 caused metastatic tumor formation in athymic 
mice (see Table 1).  Representative results depict the metastatic tumors. 
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Figure 2.15 
Histopathologic confirmation of bone and soft tissue metastasis. A, a tibial tumor (arrow) was 
identified by X-ray (Pathomorphology).  The tumor was subjected to H&E staining for 
histopathologic confirmation.  Compared to the tibia of the opposite leg (Normal), the tibial tu-
mor (Tumor) showed histopathology typical of a metastatic bone lesion.  B, an adrenal gland me-
tastasis (held by forceps) destroyed the gland (Pathomorphology).  Compared to the unaffected 
gland (Normal), tumor cells were found in every part of the affected gland (Tumor) (250 ×). 
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Figure 2.16 
LIV-1 expression is associated with human prostate cancer progression. RT-PCR and Western 
blotting were used to determine LIV-1 expression in different prostate cancer cell lines. β-actin 
was used as control in Western blotting and GAPDH was used as control for RT-PCR analysis. 
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Figure 2.17 
LIV-1 expression was correlated with prostate cancer progression. Representative IHC images 
show increased LIV-1 expression in human prostate specimens from benign to bone metastasis 
(125 ×). 
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Figure 2.18 
Statistical analysis of LIV-1 expression correlated with prostate cancer progression. Interval plot 
of LIV-1 expression is shown versus prostate cancer progression from normal/benign, PIN, pri-
mary cancer to bone metastasis.  The data was shown with 95% confidence interval (n = number 
of cases analyzed).  The median expression for LIV-1 in bone was significantly greater than 
those in normal/benign, PIN, and primary cancer (P < 0.001) and that those in primary cancer 
only (P = 0.002) as analyzed by Mann-Whitney test. 
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3 LIV-1 PROMOTES HUMAN PROSTATE CANCER EMT AND METASTASIS 
THROUGH HB-EGF SHEDDING AND CONSTITUTIVE EGFR-MEDIATED ERK 
SIGNALING 
3.1 Abstract 
 
LIV-1, a zinc transporter, is an effector molecule downstream from soluble growth fac-
tors.  This protein has been shown to promote epithelial-to-mesenchymal transition (EMT) in 
human pancreatic, breast, and prostate cancer cells.  Despite the implication of LIV-1 in cancer 
growth and metastasis, there has been no study to determine the role of LIV-1 in prostate cancer 
progression.  Moreover, there was no clear delineation of the molecular mechanism underlying 
LIV-1 function in cancer cells.  In the present communication, we found increased LIV-1 expres-
sion in benign, PIN, primary and bone metastatic human prostate cancer.  We characterized the 
mechanism by which LIV-1 drives human prostate cancer EMT in an ARCaP prostate cancer 
bone metastasis model.  LIV-1, when overexpressed in ARCaPE cells, promoted EMT irreversi-
bly.  LIV-1 overexpressed ARCaPE cells had elevated levels of HB-EGF and MMP 2 and MMP 
9 proteolytic enzyme activities, without affecting intracellular zinc concentration.  The activation 
of MMPs resulted in the shedding of HB-EGF from ARCaPE cells that elicited constitutive 
EGFR phosphorylation and its downstream ERK signaling.  These results suggest that LIV-1 is 
involved in prostate cancer progression as an intracellular target of growth factor receptor signal-
ing which promoted EMT and cancer metastasis.  LIV-1 could be an attractive therapeutic target 
for the eradication of pre-existing human prostate cancer and bone and soft tissue metastases. 
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3.2 Introduction 
 
LIV-1, a cell surface protein and a candidate mediator of the growth factor-elicited sig-
naling molecule, has been associated with several important biologic processes by serving as a 
transporter for zinc and other ions (Chowanadisai et al., 2008; el-Tanani and Green, 1996, 1997; 
Taylor et al., 2004; Taylor et al., 2003).  As a prototype of the LIV-1 subfamily of ZIP metal 
transporters (Taylor, 2000; Taylor et al., 2003), LIV-1 shares secondary structure with ZIP trans-
porters and may have the ability to transport metal ions.  LIV-1 was shown to be a mediator 
downstream from signal transducer and activator of transcription 3 (STAT3) and Snail, cooperat-
ing with Snail in the repression of epithelial marker E-cad gene transcription (Cano et al., 2000).  
LIV-1 was also shown to be an interacting partner for the estrogen receptor (ER) in hormone-
sensitive tissues (El-Tanani and Green, 1997; McClelland et al., 1998).  In ER-positive ZR-75-1 
breast cancer cell line, LIV-1 transcription is induced by estrogens (Manning et al., 1988).  In 
breast tumors, LIV-1 expression is associated with ER status (Dressman et al., 2001), and is 
positively correlated with the spread of cancer to regional lymph nodes (Manning et al., 1994).  
In cervical cancer, expression of LIV-1 was shown to be higher in tumor than normal tissues; 
RNAi-mediated suppression of LIV-1 significantly inhibited cell proliferation, colony formation, 
and reduced migratory and invasive ability of the HeLa cells (Zhao et al., 2007a).  LIV-1 has al-
so been reported to be elevated in clinical pancreatic carcinoma and induced EMT in pancreatic 
cancer cells (Unno et al., 2009).  In zebrafish, LIV-1 is essential for the nuclear localization of 
Snail, a master transcription factor promoting epithelial to mesenchymal transition (EMT), caus-
ing migration of gastrula organizing cells (Yamashita et al., 2004).  LIV-1 thus is an obligatory 
co-factor regulating EMT-associated genes (Unno et al., 2009; Yamashita et al., 2004; Zhao et 
al., 2007b). 
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Epidermal growth factor receptor (EGFR) is a member of the ErbB family of receptor ty-
rosine kinases and EGFR signaling has been well documented that desregulation of EGFR sig-
naling is involved in tumorigenesis and cancer metastasis (El-Rayes and LoRusso, 2004; Hynes 
and MacDonald, 2009).Activation of EGFR is controlled by binding of their ligands, which are 
members of the EGF family of growth factors. Ligand binding to EGFR induce receptor dimeri-
zation and intrinsic kinase domain activation, which in turn lead to the activation of subsequent 
downstream signaling events, such as mitogen-activated protein kinase (MAPK), phosphatidyl-
inositol 3-kinase (PI3K)/AKT, and signal transducers and activators of transcription (STAT) sig-
naling pathways (Fischer et al., 2003; Lurje and Lenz, 2009)which are important in regulating 
cell proliferation, migration and tumor progression. Constitutive activation of EGFR is often 
found in several malignant cancers. Mechanisms involving in the dysregulation of EGFR include 
receptor overexpression, receptor mutation or coexpression of ligands and the receptor and all 
these result in constitutively active EGFR signaling which will lead to malignant transformation 
and tumor growth (Hardy et al.).  
Heparin-binding epidermal growth factor (HB-EGF) is a member of the EGF family of 
growth factors and is involved in many biological processes including cell adhesion, invasion 
and also cancer progression (Miyamoto et al., 2006). HB-EGF is synthesized as a membrane-
anchored protein and is cleaved by zinc metalloproteases at the cell surface to release the mature 
soluble form of HB-EGF (Huang et al., 2006b). The soluble form of HB-EGF then binds to 
EGFR to cause EGFR transactivation. This proteolytic process is known as ectodomain shedding. 
Multiple zinc-binding metalloproteases of the matrix metalloprotease (MMP) and a disintegrin 
and metalloprotease (ADAM) families are reported to be involved in this ectodomain shedding 
process (Higashiyama et al., 2008; Shah and Catt, 2004). MMP2 and MMP9 are of particularly 
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interest because of their role in the regulation of HB-EGF shedding (Roudabush et al., 2000; 
Song et al., 2007) and also in early cancer development, invasion and metastasis (Mook et al., 
2004; Shen et al., 2009).     
The potential diagnostic and prognostic values of LIV-1 in human prostate cancer have 
not been investigated.  Since zinc plays important roles in the maintenance of prostate epithelial 
cell homeostasis (Bataineh et al., 2002), and Snail is a master transcription factor controlling 
prostate cancer cell EMT (Barrallo-Gimeno and Nieto, 2005; Batlle et al., 2000; Odero-Marah et 
al., 2008), LIV-1 may be an active participant in the promotion of EMT during prostate cancer 
progression and bone metastasis.  In this study, we determined the level of LIV-1 in human pros-
tate cancer cell lines and clinical tissue specimens to define the relationship between LIV-1 and 
prostate cancer progression and metastasis.  The ARCaP human prostate cancer progression cell 
model was used to evaluate the role of LIV-1.  Our study found that LIV-1 overexpression pro-
motes prostate cancer cell EMT and facilitates its metastasis to bone and soft tissues.  Further 
mechanistic investigation revealed that LIV-1 overexpression could upregulate HB-EGF and 
MMP2 and MMP9 expression.  The latter could enzymatically cleave membrane-bound HB-
EGF, to produce soluble HB-EGF that constitutively activated EGFR via increased EGFR phos-
phorylation and its downstream ERK signaling.  This is the first finding that LIV-1 overexpres-
sion could activate EGFR signaling through upregulation of HB-EGF and MMP2/ MMP9 to 
promote cancer cell invasiveness. Last, the results from this study demonstrate that molecular 
suppression of LIV-1 could be a therapeutic strategy to inhibit prostate tumor cell EMT and 
prostate cancer bone metastasis. 
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3.3 Material and Methods 
3.3.1 Cell lines and cell culture. 
 
Human prostate cancer ARCaPE and ARCaPM cells were established in our laboratory 
(21).  The cells were cultured in T-medium (Invitrogen, Carlsbad, CA) supplemented with 5% 
fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville, GA).  Human embryonic kidney 
HEK293 cells were obtained from American Type Culture Collection (Manassas, VA) and cul-
tured in DMEM (Invitrogen) supplemented with 10% FBS.  RPMI-1640 was purchased from 
Invitrogen (Carlsbad, CA).  All the culture media were supplemented with penicillin (100 U/ml) 
and streptomycin (100 μg/ml).  Cell cultures were maintained at 37°C in a humidified atmos-
phere supplemented with 5% CO2. 
 
3.3.2 Antibodies and reagents. 
 
Polyclonal rabbit antibody against LIV-1 was generated in our laboratory.  Rabbits were 
immunized by standard immunization protocol with conjugated peptide KLH-
CPDHDSDSSGKDPRNS, corresponding to residues 146-161 of the LIV-1 protein (GenBank 
accession number NM_012319).  Blood was taken 2 weeks after the fourth boost and IgG were 
purified and tested for specific immune reactivity.  Polyclonal antibody to phospho-EGFR anti-
body was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).  Monoclonal antibody to 
EGFR was from BD Transduction Laboratories (San Diego, CA).  Antibodies to p44/42 MAP 
kinase and the phosphorylated isoforms were from Cell Signaling Technology (Danvers, MA).  
Monoclonal antibody to β-actin was from Sigma-Aldrich (St. Louis, MO). 
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Growth factors of EGF was from R&D Systems (Minneapolis, MN).  Tyrphostin 
AG1478, U0126 and MMP2/9 inhibitor III were obtained respectively from Alomone labs (Jeru-
salem, Israel), Cell Signaling Technology (Danvers, MA), and Calbiochem (Darmstadt, Germa-
ny). 
 
3.3.3 Transfection. 
 
Full-length coding region for human LIV-1 cDNA was cloned and confirmed by DNA 
sequencing.  The cDNA was then cloned downstream from a cytomegalovirus early promoter in 
the mammalian expression vector pcDNA3.1/V5-His (Invitrogen).  HEK293 and ARCaPE cells 
were seeded at 3 × 105 cells per well in 6-well plates 24 hours before transfection.  The cells 
were transfected with 4 μg of the LIV-1 expression construct using 8 μl Lipofectamine 2000 
(Invitrogen).  To isolate clones stably overexpressing the LIV-1, transfected ARCaPE cells were 
treated with G418 (600 μg/ml) 2 days after the transfection.  Four individual clones overexpress-
ing LIV-1 protein (LIV#8, #12, #14 and #17) and two clones transfected with control vector 
(con1 and con2) were used for the studies. 
 
3.3.4 Semiquantitative expression analysis with RT-PCR. 
 
Total RNA was isolated from cultured cells using the RNeasy Mini kit (Qiagen, Valencia, 
CA).  From each sample, equal amount of RNA (2 μg) was used in first–strand cDNA synthesis 
reaction with the Superscript First-Strand cDNA Synthesis kit (Invitrogen).  Equal volume of 
cDNA (3 μl) from each reaction was used for PCR analysis using gene-specific oligonucleotide 
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primer pairs: 5’-GCAATGGCGAGGAAGTTATCT-3’ and 5’-
CTATTGTCTCTAGAAAGTGAG-3’ for LIV-1; 5’-TGCCCAGAAAATGAAAAAGG-3’ and 
5’-GTGTATGTGGCAATGCGTTC-3’ for E-cad; ; 5’-CCATCACTCGGCTTAATGGT-3’ and 
5’-GATGATGATGCAGAGCAGGA-3’ for N-cad; 5’-CGAAAGGCCTTCAACTGCAAAT-3’ 
and 5’-ACTGGTACTTCTTGACATCTG-3’ for Snail; and 5’-TTAGCACCCCTGGCCAAGG-3’ 
and 5’-CTTACTCCTTGGAGGCCATG-3’ for GAPDH.  The reactions were initiated with a 4-
minute incubation at 94°C, followed by 30 cycles at 94°C for 30 seconds, 55°C for 30 seconds, 
and 72°C for 1 minute.  The reaction was completed with a 7-minute extension at 70°C for 7 
minutes.  PCR products were visualized after electrophoresis through a 1.2% agarose gel and 
stained by ethidium bromide (0.5 μg/ml). 
 
3.3.5 Western blotting.  
  
Cells at 80% confluence were lysed in a whole-cell lysis buffer as previously reported 
(22).  The lysates were incubated on ice for 30 minutes and centrifuged at 10,000 rpm at 4°C for 
10 minutes.  From each sample, 35 μg protein in the supernatant was resolved by SDS-PAGE 
and blotted onto a nitrocellulose membrane (BioRad, Hercules, CA), which was blocked in 5% 
skim milk in PBST (137 mM NaCl, 12 mM phosphate, 2.7 mM KCl, and 0.1% Tween 20) at 
room temperature for 20 minutes; and incubated with primary antibody at 4°C overnight.  The 
membranes were then washed three times in PBST, and incubated with horseradish peroxidase-
conjugated secondary antibody for 1 hour at room temperature.  After five washings in PBST, 
specific signal was detected by incubating the membrane with ECL reagent (Amersham-
Pharmacia Biotech, Piscataway, NJ). 
94 
3.3.6 Measuring intracellular zinc concentration. 
 
Two methods were used to determine intracellular zinc concentration.  To prepare sam-
ples for assaying total intracellular zinc by the inductively coupled plasma mass spectrometry 
(ICP-MS), cultured cells at 80% confluence were trypsinized and washed in PBS, and were then 
incubated in 300 µl of 70% nitric acid at 37°C for 2 hours.  The cells were then placed in 2% ni-
tric acid and subjected to ICP-MS with a Varian instrument.  A standard curve was generated 
with serial dilutions of zinc instrument standards.  To prepare samples for assaying intracellular 
labile zinc by fluorometric method, cells were seeded at 3 × 105 cells per well in 6-well plates 
the day before measurement.  The cells were loaded with 2 μM of FluoZIN-3 AM (Invitrogen) 
for 1 hour in Opti-MEM containing 0.02% Pluronic F127 (Invitrogen).  After washing in PBS, 
the loaded cells were incubated in indicator-free Opti-MEM for 30 minutes.  Fluorescence of the 
FluoZin-3 was measured using a PE Victor3 V plate reader. 
 
3.3.7 Trans-well migration and invasion assays.   
 
To perform a trans-well migration assay, 2.5 × 104 cells in the top chamber of 24-well 
trans-well plates of 8 µm pore size (BD Biosciences) were incubated for 16 hours in complete 
medium that was added to the bottom chamber.  Cells were then fixed with formalin and stained 
with 0.5% crystal violet.  The non-migrated cells inside the chamber were removed by swabbing.  
Crystal violet of the migrating cells was solubilized into the Sorenson’s buffer (0.1 M sodium 
citrate and 50% ethanol, pH 4.2) and was measured for absorbance at OD590.  Invasion assay 
was performed using BD BioCoat Matrigel invasion chambers (BD Biosciences; 8-µm pore size).  
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The same procedures described above were used, except the filters were pre-coated with 100 μl 
Matrigel at a 1 : 4 dilution in RPMI-1640. 
 
3.3.8 Gelatin zymography. 
 
All gelatin zymography reagents were purchased from Invitrogen.  Cells were cultured in 
serum-free RPMI1640 medium for 24 hours and conditioned medium was collected.  Protein in 
the medium was concentrated with AmiconUltracel 30 KDa filter (Millipore, Billerica, MA).  
Equal amount of protein (10 μg/sample) was mixed with 2× Novex Tris-Glycine SDS sample 
buffer, and fractionated on a 10% gelatin gel under non-reducing conditions.  The gel was then 
incubated at 37°C in renaturing buffer for 30 minutes and in developing buffer for 30 minutes.  
Finally, the gel was stained in SimplyBlue Safestain, and bands representing gelatinase activity 
of MMP2 and MMP9 were quantified. 
 
3.3.9 Enzyme-linked immunosorbent assay (ELISA) for HB-EGF. 
 
Cells were cultured in serum-free RPMI1640 medium for 24 hours.  Conditioned medium 
was collected and analyzed for HB-EGF concentration with the Human HB-EGF Duoset ELISA 
kit (R&D Systems), following manufacturer’s recommended protocol.  Basically, a 96-well plate 
was coated with the HBEGF capture antibody and incubated overnight at room temperature. The 
plate was then washed three times with wash buffer and blocked by adding reagent diluents for at 
least 1 hour at room temperature. The plate was washed twice with wash buffer and added with 
HBEGF condition medium, incubating 2 hours at room temperature.  The plate was then washed 
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three times with wash buffer and added with the HBEGF detection antibody, incubating 2 hours 
at room temperature. The plate again was washed three times with wash buffer and added with 
Streptavidin-HRP, incubating 20 minutes at room temperature. Repeat the wash steps and then 
substrate was added to each well for 20 minutes at room temperature. Next, stop solution was 
added to each well and optical density at OD 450 was measured by using a plate reader (subtrac-
tion of OD 540). The results were plotted. Each sample was assayed in triplicate from three inde-
pendent experiments. 
 
3.4 Results 
3.4.1 LIV-1 overexpression activates EGFR and downstream ERK signaling. 
 
Our previous study showed that LIV-1 induced EMT in vitro and promoted prostate can-
cer metastasis in vivo. We next explored the mechanism by which LIV-1 promoted prostate can-
cer EMT, progression and metastasis.  We examined the phosphorylation status of AKT, p38, 
JNK, Smad, NF-κB, β-catenin and ERK because these regulatory proteins were shown to be al-
tered by a soluble growth factor, β2-M, which also promoted EMT and LIV-1 expression (Gra-
ham et al., 2008; Josson et al., ; Zhau et al., 2008).  In this study, we observed that ERK signal-
ing was significantly activated (Figure 3.1).  ERK signaling has been well studied that p-ERK is 
involved in cell proliferation, migration, invasion as well as metastasis. Since ERK was frequent-
ly activated by growth factor receptor signaling, we examined specifically the phosphorylation 
status of IGF-1R, TGF-β receptor and EGFR proteins.  This series of analyses revealed that there 
was a specifically increased EGFR phosphorylation in the LIV-1-overexpressing cells (Figure 
3.1).  To elucidate the relationship between EGFR and ERK activation, we used the specific in-
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hibitor AG1478 to block EGFR activation.  After AG1478 treated the cells for 2 hours, whole 
cell lysates was collected to further do Western blotting analysis. Inhibition of EGFR phosphory-
lation led to a simultaneous reduction in ERK phosphorylation (Figure 3.2), suggesting that 
EGFR activation is responsible for downstream ERK phosphorylation. 
 
3.4.2 Block of EGFR and ERK signaling reduce migratory and invasive abilities of the 
LIV-1 overexpressing cells. 
 
We examined next whether EGFR-induced ERK activation were responsible for the in-
creased metastatic behaviors of LIV-1 overexpressing ARCaPE cells in transwell migration and 
invasion assays.  Blocking EGFR activation by AG1478 was accompanied by reduced migratory 
and invasive capabilities (Figure 3.3).  In support of these results, ERK inhibitor U0126 treat-
ment also reduced both the migratory and invasive capabilities (Figure 3.4), similar to those ob-
served following AG1478 treatment.  These results, taken together, demonstrated that EGFR and 
downstream ERK activation is the major signaling pathway stimulating migratory and invasive 
behavior of the LIV-1 overexpressing cells. 
 
3.4.3 LIV-1 overexpression did not enhance intracellular zinc concentration of LIV-1 
overexpressing cells. 
 
Since LIV-1 is a member of the ZIP metal transporters that may regulate intracellular 
zinc ion homeostasis (Chowanadisai et al., 2008; Lopez and Kelleher, ; Taylor et al., 2003), we 
evaluated whether the increased EGFR constitutive phosphorylation in LIV-1 overexpressing 
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clones was due to changes in intracellular zinc concentration.  Intracellular labile Zn was as-
sessed with Zn-specific fluorophores and LIV-1-overexpressing cells showed very slightly in-
crease of labile Zn when compare to control cells (Figure 3.5). Total intracellular zinc concentra-
tion measured by ICP-MS did not show big differences between ARCaPE-LIV-1and ARCaPE-
neo cells (Figure 3.6). As a summary, compared to the control clones, there were no statistically 
significant differences in both the total zinc determined by ICP-MS analysis and the labile frac-
tion measured with fluorometric assay method (Figure 3.5&3.6). 
 
3.4.4 LIV-1 activated EGFR signaling by increasing HB-EGF, MMP2 and MMP9 expres-
sion. 
 
We then tested the hypothesis that as a result of activation of EGFR in LIV-1 overex-
pressing cells, a positive feedback consisting of an autocrine/paracrine loop of growth factors 
may be elicited to account for increased tumorigenicity and metastatic potential.  We examined 
whether the increased EGFR phosphorylation was a result of increased production of cognate 
ligands such as EGF and HB-EGF proteins (Fischer et al., 2003; Lurje and Lenz, 2009). 
Western blotting revealed that LIV-1 overexpressing ARCaPE clones and the control 
clones had similar levels of EGFR protein, and upon ligand treatment both clones could be dras-
tically phosphorylated, which was abolished by specific inhibitor AG1478 (Figure 3.7).  None-
theless, LIV-1 overexpressing LIV-1 cells showed a constitutive EGFR phosphorylation in the 
absence of exogenous ligand, and this phosphorylation could be abolished by AG1478 treatment 
(Figure 3.7).  To investigate the cause of the constitutive EGFR phosphorylation, we found while 
both of these cell types produced low or undetectable levels of EGF as detected by RT-PCR, sig-
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nificant increased levels of HB-EGF were expressed by LIV-1 overexpressing clones compared 
to the control clones (Figure 3.8).  These results indicated that HB-EGF may be a constitutive 
inducer for EGFR signaling via increased EGFR phosphorylation. 
 
3.4.5 Increase of MMP2 and MMP9 activity caused an increase of soluble HB-EGF, 
which in turn activates EGFR signaling. 
 
HB-EGF is synthesized as a membrane-anchored form which needs to be released from 
the plasma membrane by matrix metalloproteases (MMPs) in order to bind EGFR (Miyamoto et 
al., 2006; Roudabush et al., 2000; Song et al., 2007).  Interestingly, there was significantly higher 
MMP2 and MMP9 expression in the LIV-1-overexpressing clones (Figure 3.8), while gelatin 
zymography demonstrated that MMP2 and MMP9 enzymatic activities were also enhanced (Fig-
ure 3.9).  Importantly, treatment with MMP2/9 inhibitor III led to a sensitive reduction of soluble 
HB-EGF in the culture media as determined by ELISA (Figure 3.10), suggesting that these 
proteolytic enzymes were involved in HB-EGF shedding.  In other experiments, MMP2/9 inhibi-
tor III treatment caused a time-dependent loss of phosphorylation in both EGFR and the down-
stream ERK proteins (Figure 3.11), confirming that the proteolytic enzymes acted upstream of 
EGFR-elicited MAPK signaling.  Consequently, MMP2/9 inhibition significantly reduced the 
migratory and invasive ability of LIV-1-overexpressing cells in transwell assays (Figure 3.12).  It 
seemed likely that the function of LIV-1 was to stimulate the expression of MMP2, MMP9 and 
HB-EGF proteins, which in turn activated EGFR and downstream ERK signaling, leading to 
EMT that facilitated local tumor growth and its distant metastases to bone and soft tissues (Fig-
ure 3.13). 
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Figure 3.1 
LIV-1 overexpressing cells (LIV#8 and LIV#14) showed increased phosphorylated EGFR (p-
EGFR) and ERK (p-ERK).  
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Figure 3.2 
EGFR inhibitor (AG1478) treatment reduced phosphorylated EGFR and ERK in LIV-1 overex-
pressing cells. 
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Figure 3.3 
Inhibition of EGFR suppressed migratory ability and invasive ability of LIV-1 overexpressing 
clones in transwell assays 24 hours after the treatment. * indicates statistical significance com-
pared to the control of the same group (P < 0.05). 
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Figure 3.4 
Inhibition of ERK signaling resulted in similar suppression of cellular motility to the EGFR inhi-
bition.  * indicates statistical significance compared to the control of the same group (P < 0.05). 
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Figure 3.5 
Intracellular labile Zn was assessed with Zn-specific fluorophores and measured by a fluores-
cence plate reader.  
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Figure 3.6 
Total intracellular zinc concentration was measured by ICP-MS. 
 
 
 
 
 
 
0 
5 
10 
15 
20 
25 
30 
LIV#8 LIV#14 con1 con2 ARCaPE ARCaPM 
Zi
nc
 c
on
ce
nt
ra
tio
n 
(p
pb
/1
0*
5 
ce
lls
) 
106 
 
Figure 3.7 
Treatment of EGF and EGFR inhibitors in LIV-1 overexpressing cells. LIV-1 overexpressing 
cells (LIV#8) and control cells (con1) were treated with EGF and AG1478 for 2 hours.  Western 
blotting showed that the EGF-elicited EGFR and ERK phosphorylation was blocked by the 
AG1478 inhibitor. 
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Figure 3.8 
RT-PCR showed increased HB-EGF, MMP2 and MMP9 expression in LIV-1 overexpressing 
cells. 
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Figure 3.9 
MMP2/9 activity was higher in LIV-1 overexprssing cells. LIV-1 overexpressing cells (LIV#8 
and LIV#14) were cultured in serum-free medium for 24 hours and the culture media were used 
to determine the MMP2 and MMP9 enzymatic activity by zymogram assay. 
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Figure 3.10 
The effect of MMP2/9 enzymatic activity on HB-EGF shedding was evaluated by ELISA.  LIV-
1 overexpressing clones (LIV#8 and LIV#14) secreted more HB-EGF than control clones (con1 
and con2), and the secretion was reduced by MMP2/9 inhibition.  ٭indicates statistical signifi-
cance compared to the control of the group (P < 0.05). 
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Figure 3.11 
Treatment of MMP2/9 inhibitors reduced the levels of phosphor-EGFR and downstream phos-
phor-ERK. Western blotting showed that inhibition of MMP2/9 activity suppressed EGFR and 
the downstream ERK phosphorylation. 
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Figure 3.12 
Treatment of MMP2/9 inhibitors decreased migratory and invasive ability of LIV-1 overexpress-
ing cells. LIV-1 overexpressing cells were treated with MMP 2/9 inhibitor III for 24 hours in 
Transwell motility assays.  Both migration and invasion of the treated cells were decreased.  * 
indicates statistical significance compared to the control of the group (P < 0.05).  
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Figure 3.13 
Diagram depicts the proposed role of LIV-1 in prostate cancer cell EMT and metastasis. 
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4 LIV-1 UPREGULATES HB-EGF PROMOTER ACTIVITY THROUGH AP-1 AND 
STAT3 TRANSCRIPTION FACTORS 
4.1 Abstract 
 
LIV-1, a zinc transporter, is an effector molecule downstream from soluble growth fac-
tors. LIV-1 overpression has been shown to induce EMT and cancer progression. LIV-1 overex-
pression enhanced tumor cells with increased migratory and invasive capability. Constitutive ac-
tivation of EGFR signaling has been demonstrated to be the major signaling contributing the ma-
lignant phenotype of tumor cells. The function of LIV-1 was seemed to stimulate the expression 
of MMP2, MMP9 and HB-EGF proteins, which in turn activated EGFR and downstream signal-
ing, leading to EMT that facilitated local tumor growth and its distant metastases to bone and 
soft tissues. Here we found that up-regulation of HB-EGF promoter activity was significantly 
increased in LIV-1 overexpressing cells and AP-1 and Stat3 were the two major transcription 
factors controlling HB-EGF promoter activity. Blockade of AP-1 and Stat3 activity diminished 
the HB-EGF promoter activity. In addition, ChIP experiments showed that both AP-1 and Stat3 
bound to HB-EGF promoter in vivo, and specific inhibitors of AP-1 and Stat3 inhibited the bind-
ing of these transcription factors to the promoter. This study provides a new understanding of the 
mechanism of LIV-1 driven cancer metastasis and may help to develop a better strategy of anti-
tumor therapy. 
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4.2 Introduction 
 
LIV-1 was first identified in the breast cancer cell line ZR-75-1 as an estrogen-regulated 
gene(el-Tanani and Green, 1995), and is predominately expressed in hormonal controlled tissues 
with high levels in breast, prostate, pituitary gland and brain(Taylor et al., 2003). EMT has been 
implicated in the progression of many solid tumors, including prostate cancer (Whitbread et al., 
2006; Xu et al., 2006; Zhau et al., 2008)and is considered as a key molecular event in cancer 
progression(Thiery, 2003). LIV-1 was reported to induce EMT in zebrafish gastrula organizing 
cells (Yamashita et al., 2004).  LIV-1 mRNA was recently shown to be higher in cervical cancer 
in situ than in normal tissues(Zhao et al., 2007a).  RNAi mediated suppression of LIV-1 in HeLa 
cells significantly inhibited their proliferation, colony formation, migratory, and invasive ability 
(Zhao et al., 2007b).  Ours and other studies have demonstrated that LIV-1 expression was ele-
vated in clinical prostate and pancreatic carcinoma and induced EMT in prostate and pancreatic 
cancer cells (Unno et al., 2009).  However, LIV-1 expression was also reported to correlate with 
E-cadherin expression(Shen et al., 2009) and be associated with better outcome of breast cancer 
patients(Kasper et al., 2005).  
HB-EGF is a member of EGF family of growth factors and its expression is found to be 
increased in a lot of different cancer types. For example, HB-EGF expression was one or two 
orders of magnitude higher than other EGF family members in ovarian cancer patients (Miya-
moto et al., 2004). In bladder cancer, HB-EGF was also been shown to express ten to hundred 
fold higher than other EGFR ligands (Thogersen et al., 2001), indicating that HB-EGF might be 
the major ligand which is responsible for EGFR activation at least in ovarian and bladder cancers. 
HB-EGF has been shown to promote prostate cancer cell migration and invasion 
(Madarame et al., 2003). Recently, studies demonstrated that HB-EGF is involved in EMT in 
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gastric and ovarian cancer cells (Yagi et al., 2008; Yin et al.). Treatment of recombinant HB-
EGF protein in ovarian cancer cells decreased E-cadherin expression but increased Snail expres-
sion (Yagi et al., 2008). In addition, overexpression of non-cleavable HB-EGF increased E-
cadherin expression and decreased cell motility in pancreatic cancer cells (Wang et al., 2007a), 
suggesting a role of cancer metastasis. 
The HB-EGF gene is expressed in a variety of cells and tissues and its expression has 
been shown to be induced by lots of signals, such as growth factors, tumor necrosis factor α, 
phorbol ester, thrombin and angiotensin II. HB-EGF gene is highly expressed in smooth muscle 
cells and MyoD, AP-1 and Ets-2 have been indicated in stimulating HB-EGF mRNA expression 
through binding to its promoter region during myogenesis, oxidative stress and oncogenic raf 
(Chen et al., 1995; McCarthy et al., 1997; Sakai et al., 2001). In addition, regulatory macrophag-
es upregulate HB-EGF mRNA transcription through Sp-1 transcription factors (Edwards et al., 
2009). Knockdown of Sp-1 abrogates HB-EGF expression by regulatory macrophages.  
Previous studies showed that overexpression of LIV-1 induced EMT and cancer metasta-
sis through HB-EGF shedding mediating EGFR activation. Here we demonstrated that HB-EGF 
promoter activity was significantly increased in LIV-1 overexpressing cells. AP-1 and Stat3 tran-
scription factors were found to be essential for HB-EGF promoter activation in LIV-1 overex-
pressing cells. Blockade of AP-1 and Stat3 completely suppressed HB-EGF promoter activity. 
Since AP-1 and Stat3 have been found to play critical roles in cancer metastasis, the purpose of 
this study is to investigate the molecular mechanism of HB-EGF promoter activity and evaluate 
the therapeutic potential of HB-EGF induced cancer metastasis.  
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4.3 Material and Methods 
4.3.1 Cell lines and cell culture. 
 
Human prostate cancer ARCaPE and ARCaPM cells were established in our laboratory 
(Xu et al., 2006).  The cells were cultured in T-medium (Invitrogen, Carlsbad, CA) supplement-
ed with 5% fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville, GA).  Human embry-
onic kidney HEK293 cells were obtained from American Type Culture Collection (Manassas, 
VA) and cultured in DMEM (Invitrogen) supplemented with 10% FBS.  All the culture media 
were supplemented with penicillin (100 U/ml) and streptomycin (100 μg/ml).  Cell cultures were 
maintained at 37°C in a humidified atmosphere supplemented with 5% CO2. 
 
4.3.2 Antibodies and reagents. 
 
Antibody to c-Jun (ChIP grade) was from Abcam (Cambridge, MA).  Antibody to phos-
phor-Stat3 (Tyr705) was from Cell Signaling Technology (Danvers, MA).  Monoclonal antibody 
to β-actin was from Sigma-Aldrich (St. Louis, MO). Antibody to RNA Polymerase II and mouse 
IgG were from Upstate (Billerica, MA). SB203580 and U0126 were obtained from Cell Signal-
ing Technology (Danvers, MA). MMP2/9 inhibitor III, Stat3 inhibitor (WP1066) and AP-1 in-
hibitor (SR11302) were obtained respectively from Calbiochem (Darmstadt, Germany), Santa 
cruz biotechnology (Santa Cruz, CA), and Tocris Bioscience (Ellisville, Missouri). 
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4.3.3 Transfection. 
 
HEK293 and ARCaPE cells were seeded at 3 × 105 cells per well in 6-well plates 24 hours 
before transfection.  The following morning the cells were transfected with 4 μg of the promoter 
and expression vector construct using 8 μl Lipofectamine 2000 (Invitrogen). First, 4 μg of the 
promoter and expression vector construct were diluted in 250μl Opti-Mem reduced serum media 
(Invitrogen). Then, 250μl of Opti-Mem containing 8 μl of Lipofectamine 2000 was added to 
250μl Opti-Mem containing 4 μg of the promoter and expression vector constructs. The complex 
was incubated for 30 minutes at room temperature and then added directly to the well. The cells 
were allowed to incubate for 6 hours at 37  ̊C. The complex was removed and 2 ml of fresh cul-
ture media was added to each well. Cells were typically harvested at 24-48 hours post-
transfection. 
 
4.3.4 Drug treatment of cells. 
 
Drug treatment of cells allows for the examination of different cellular pathways. Cells 
were serum starves for approximately 18-24 hours before treatment. As a control, the substance 
used to dissolve the drug was added to cells alone. Once the treatment was complete the cells 
were harvested for further analysis. 
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4.3.5 Dual Luciferase Reporter assay. 
 
Dual Luciferase Reporter assay system (Promega) was used to analyze promoter activity. 
Cells were transfected with a firefly promoter plasmid and a renilla reporter plasmid as a internal 
control with or without an expression plasmid. After 24-48 hours post-transfection, the cells 
were directly lysed using 1X Lysis buffer rocking at room temperature for 15-20 minutes. 20 μl 
of the cell lysate was added to a 96 well plate and then 100 μl of the Luciferase substrate was 
added to the sample. The samples were read on an EnSpire® Multimode Plate Reader (Perki-
nElmer) to read the firefly luciferase activity first. Then the Stop-&- Glo reagent was added to 
the sample and measure again to read the control Renilla activity. The results were a normaliza-
tion of the Firefly with Renilla luciferase RLU (Firefly/Renilla) from each sample. 
 
4.3.6 Semiquantitative expression analysis with RT-PCR. 
 
Total RNA was isolated from cultured cells using the RNeasy Mini kit (Qiagen, Valencia, 
CA).  From each sample, equal amount of RNA (2 μg) was used in first–strand cDNA synthesis 
reaction with the Superscript First-Strand cDNA Synthesis kit (Invitrogen).  Equal volume of 
cDNA (3 μl) from each reaction was used for PCR analysis using gene-specific oligonucleotide 
primer pairs: 5’- TGCCCGGCGGAATCTCCTGA -3’ and 5’- 
GATGCAGGAGGGAGCCCGGA -3’ for HB-EGF; and 5’-TTAGCACCCCTGGCCAAGG-3’ 
and 5’-CTTACTCCTTGGAGGCCATG-3’ for GAPDH.  The reactions were initiated with a 4-
minute incubation at 94°C, followed by 32 cycles at 94°C for 30 seconds, 55°C for 30 seconds, 
and 68°C for 1 minute.  The reaction was completed with an extension at 68°C for 10 minutes.  
119 
PCR products were visualized after electrophoresis through a 1.2% agarose gel and stained by 
ethidium bromide (0.5 μg/ml). 
4.3.7 Chromatin Immunoprecipitation (ChIP). 
 
EZ-ChIP™ kit from Upstate was used to analyze whether a specific transcription factor 
binds to a known segment of DNA. Cells were seeded in 100 mm culture dishes in culture media 
so that the following day the confluence would be approximately 90% . Cells were crosslinked 
by adding Formaldehyde to a final 1% concentration. The cells were incubated for 10minutes at 
room temperature. Next, 10X glycine (final concentration 1X) was added to quench unreacted 
formaldehyde and the cells were incubated for 5 minutes at room temperature. The medium was 
removed and the cells were washed twice with ice-cold 1x PBS. The cells were harvested in 2 ml 
PBS containing 1X protease inhibitor cocktail II and centrifuged at 700 g at 4 ̊C for 2-5 minutes. 
The cells were then lyzed in 1 ml SDS Lysis Buffer containing 1X Protease Inhibitor Cocktail II.  
After Lysis, the samples were sonicated in an ice-water bath with 12 sets of 15-second pulses 
and 45-second off so that the size of the DNA fragment would be 200-1000 base pairs.  The 
samples were then centrifuged to remove the insoluble materials. 900 μl of Dilution Buffer was 
added to a 100 μl aliquot of each sample and 60 μl of Protein G Agarose was then added to 
preclear the lysate. Prior immunoprecipitation, a 20 μl precleared lysate was aliquote as an input 
control. Next, immunoprecipitation was performed with 1-5 μg of anti-phospho Stat3 or anti-c-
Jun antibodies overnight at 4 ̊C with rotation. For positive control, anti-RNA polymerase Ii was 
used. For negative control, normal mouse IgG was used. The following day 60 μl of Protein G 
Agarose beads was added to each sample and incubated for 1 hour at 4 ̊C with rotation. The 
samples were centrifuged at 1200 rpm for 1 minute and the supernatant was removed. The beads 
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were then washed with 1 ml each of the cold biffer in the order, Low Salt Immune Complex 
Wash Buffer, High Salt Immune Complex Wash Buffer, LiCl Immune Complex Wash Buffer, 
and TE Buffer twice. Following the wash, 100ul of elution buffer (20% SDS, 0.1M NaHCO3) 
was added to the beads and incubate for 15 minutes at room temperature to elute the pro-
tein/DNA complex. This step was repeated and total of 200 μl eluted sample were collected. The 
eluted chromatin was then subjected to reverse crosslinking by adding 8 μl of 5M NaCl and in-
cubated at 65 ̊C overnight. The samples was then added 1 μl of RNase A and incubate at 37 ̊C for 
30 minutes. Next, 4 μl 0.5 M EDTA, 8 μl 1M Tris-HCl and 1 μl Proteinase K were added to each 
sample and the samples were incubated at 45 ̊C for 1-2 hours. The DNA was then purified by 
using Spin Columns and the purified DNA was analyzed with Real-time quantitative PCR. 
 
4.3.8 Real-time Quantitative PCR.  
 
2 μl of purified DNA, 250 nM of the appropriate primers, 1X Fast SYBR Green master 
mix (Applied Biosystems) and ddH2O to 20 μl in a MicroAmp fast 96-well Reaction Plate (Ap-
plied Biosystems). The plate was covered with a MicroAmp Optical Adhesive Film (Applied 
Biosystems). The reaction was performed in the Applied Biosystems 7500 Fast Real time system. 
The primers were listed below: Stat3-F: 5’-AGGGAGGGACAGTGGGATAG-3’; Stat3-R: 5’-
CTTCCAACCCATGTGCTTTT-3’; AP-1-F: 5’-AAACAACTCTCTCCCCAGCA-3’; AP-1-R: 
5’-TTTGACTGCCACCTTTTTCC-3’; GAPDH-F: 5’-TACTAGCGGTTTTACGGGCG-3’; 
GAPDH-R: 5’-TCGAACAGGAGGAGCAGAGAGCGA-3’. The reactions were initiated with 
15 seconds incubation at 94°C, followed by 40 cycles at 94°C for 3 seconds, 60°C for 30 seconds. 
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The Ct values were measured and relative Ct method was used to do the following analysis. The 
results were expressed as a fold difference manner (2-(ddCt)) and plotted in chart form. 
 
4.3.9  Site-directed Mutagenesis. 
 
QuikChange II Site-Directed Mutagenesis Kit (Stratagene) was used to generate the de-
sire mutations. Mutagenesis primers were designed using Stratagene’s Primer Design program. 
For Stat3 Mutant: sense- 5'-acgcgtcacgtccctggccactgaaatacctactgag-3'; antisense- 5'-
ctcagtaggtatttcagtggccagggacgtgacgcgt-3'. For AP-1 Mutant1: sense- 5'-
atttctttgggtcaggacagagatcccagaagacccctgcaaaag-3'; antisense-5'-
cttttgcaggggtcttctgggatctctgtcctgacccaaagaaat-3'. For AP-1 Mutant2: sense- 5'-
agctgggtcctatgggagggaggtccattttttatgttgaggaaaa-3'; antisense- 5'-
ttttcctcaacataaaaaatggacctccctcccataggacccagct-3'. PCR was performed with the HB-EGF pro-
moter construct and the mutagenesis primers according to manufacturer’s protocol. After PCR, 
Dpn I was added to the reaction and incubated for 1 hour at 37 ̊C to remove the unmutated plas-
mid DNA. Then the mutated plasmid was transformed and the colonies were chosen and sent for 
sequencing to confirm mutation. 
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4.4 Results 
4.4.1 LIV-1 overexpressing cells up-regulates the transcription of HB-EGF through a 
phosphor-ERK and phosphor-Stat3 dependent pathway. 
 
Previous studies we have shown that LIV-1 promoted prostate cancer EMT, progression 
and metastasis. The function of LIV-1 was to stimulate the expression of MMP2, MMP9 and 
HB-EGF proteins.  MMP2 and MMP9 then cleaved membrane-bound HB-EGF to release more 
soluble form of HB-EGF, which in turn activated EGFR to activate EGFR and downstream p-
ERK and p-Stat3 signaling pathways, leading to EMT that facilitated local tumor growth and its 
distant metastases to bone and soft tissues. In addition, we found that inhibition of MMP2/9 re-
sulted in a sensitive reduction of EGFR activation as well as downstream p-ERK and p-Stat3 
signaling (Figure 4.1). 
Since LIV-1 overexpressing cells expressed higher HB-EGF mRNA as well as soluble 
HB-EGF in culture media (Figure 4.2), We then examined whether the increase of HB-EGF 
mRNA was due to increase in HB-EGF transcription. We used a 1.1kb human HB-EGF promot-
er following a firefly luciferase reporter and transfected the HB-EGF promoter with a renilla re-
porter as an internal control into LIV-1 overexpressing cells and control cells. We found that 
HB-EGF promoter activity showed a 4-5 fold of increase in LIV-1 overexpressing cells compar-
ing to control cells (Figure 4.3). This result suggested that LIV-1 overexpression causes a tran-
scriptional increase of HB-EGF expression. Next, we explored the mechanism controlling HB-
EGF transcription.  In previous study, we examined the phosphorylation status of AKT, p38, 
JNK, Smad, NF-κB, β-catenin and ERK in LIV-1 overexpressing cells because these regulatory 
proteins were shown to be altered by a soluble growth factor, β2-M, which also promoted EMT 
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and LIV-1 expression. We observed that two major signaling pathways were significantly acti-
vated which are p-ERK and p-Stat3 (Figure 4.4). To test whether p-ERK and p-Stat3 were in-
volved in the activation of HB-EGF transcription, we performed the promoter assay with differ-
ent drug treatment. We used U0126 and Stat3 inhibitor to block p-ERK and p-Stat3 activation 
and we also include a p38 MAPK inhibitor which has been shown to regulate HB-EGF expres-
sion. We observed that both U0126 and Stat3 inhibitor suppressed HB-EGF promoter reporter 
activity, but not SB203580 (Figure 4.5). Additionally, we treated LIV-1 overexpressing cells and 
control cells with U0126 and Stat3 inhibitor and isolated total mRNA to do a RT-PCR analysis. 
The result also showed that HB-EGF mRNA was significantly reduced (Figure 4.6). These re-
sults suggested that LIV-1 overexpressing cells may up-regulate the transcription of HB-EGF 
through a phosphor-ERK and phosphor-Stat3 dependent pathway. 
 
4.4.2 Stimulation of the HB-EGF promoter is mediated by AP-1 and phosphor-Stat3 
transcription factors. 
 
Since p–ERK and p-Stat3 are involved in the stimulation of HB-EGF promoter activity, 
we then explored whether AP-1 transcription factor could be the one to regulate HB-EGF pro-
moter activity. AP-1 has been shown to stimulate mouse HB-EGF promoter in mouse smooth 
muscle cells. In addition, AP-1 is one of the major downstream transcription factor activated by 
p-ERK and multiple potential AP-1 response elements has been found in HB-EGF promoter se-
quence by using computer software. We then test whether AP-1 is involved in stimulating HB-
EGF promoter activity. To this end, we first used an AP-1response element-luciferase construct 
to transfect into LIV-1 overexpressing cells and control cells to see whether AP-1 has been acti-
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vated. Clearly, AP-1-luc activity was 6 fold higher in the LIV-1 overexpressing cells comparing 
to control ones, indicating that AP-1 was activated in LIV-1 overexpressing cells. Furthermore, 
the increased AP-1-luc activity could be reduced by treating AP-1 inhibitors (Figure 4.7); indi-
cating that AP-1 is activated and AP-1 inhibitors could successfully reduce AP-1 binding to its 
response element.  Next, a similar experiment was carried out with transfecting a HB-EGF pro-
moter reporter and treating with or without AP-1 inhibitors. We found that HB-EGF promoter 
activity could be reduced to half by treating AP-1 inhibitors, suggesting that AP-1 might be in-
volve in the stimulation of HB-EGF transcription(Figure 4.8). We further confirmed that AP-1 
and p-ERK acted in the same pathway. Since both U0126 and AP-1 inhibitor could reduce HB-
EGF promoter activity, but no additive effect has been observed with two drugs treating at the 
same time (Figure 4.9).   
Previously we have shown that Stat3 inhibitor suppressed HB-EGF promoter activity, we 
then used a Stat3 constitutive active expression construct and a dominant negative construct to 
rule out the toxicity and specificity effect of the drug treatment. HB-EGF promoter reporter was 
co-transfected with a Stat3 constitutive active expression construct or a dominant negative con-
struct into ARCaPE cells. Clearly, HB-EGF promoter activity was stimulated by co-transfecting a 
Stat3 constitutive active expression construct and was a little bit lower by co-transfecting a Stat3 
dominant negative expression construct (Figure 4.10). Similar result has been observed when 
transfecting into HEK293 cells (data not shown). Since both AP-1 and Stat3 inhibitor could re-
duce HB-EGF promoter activity, we next explored whether HB-EGF promoter activity would be 
diminished by treating AP-1 and Stat3 inhibitors simultaneously. The result showed that treat-
ment of AP-1 and Stat3 inhibitors completely blocked HB-EGF promoter activity in LIV-1 over-
expressing cells (Figure 4.11). Additionally, we treated LIV-1 overexpressing cells and control 
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cells with U0126, Stat3 inhibitor or both and isolated total mRNA to do a RT-PCR analysis. The 
result also showed that HB-EGF mRNA was significantly reduced (Figure 4.12).  These results 
indicated that AP-1 and Stat3 are the major transcription factors stimulating HB-EGF transcrip-
tion.  
 
4.4.3 Between -1022 and -682on the HB-EGF promoter is necessary for promoter activity 
in LIV-1 overexpressing cells. 
 
Serial deletions of HB-EGF promoter luciferase reporter constructs were generated in or-
der to locate the responsive element. We used PCR to subclone FL, Del1 and Del2 promoter first 
to Topo TA vector. Next, we used restriction enzyme to cut the fragment and subcloned to pGL3 
basic vector (Figure 4.13). Since there were two potential Stat3 binging elements, we want to 
map the Stat3 binding position. FL, Del1, or Del2 promoter reporter construct was co-transfected 
with a Stat3 constituve or dominant negative expression vector into ARCaPE cells. Only FL 
promoter reporter construct was able to stimulate by a constitutive Stat3 (Figure 4.14), indicating 
that responsive element necessary for Stat3 stimulation lies between -1022 to -682. We further 
transfected FL, Del1, or Del2 promoter reporter construct into LIV-1 overexpressing cells and 
control cells. Del1 and Del2 promoter construct diminished all the promoter activity comparing 
to the FL promoter reporter construct ( Figure 4.15), suggesting that both AP-1 and Stat3 stimu-
late HB-EGF promoter activity through this region (-1022 to -682). Furthermore, Del1 and Del2 
promoter construct did not showed any effect by treating with a Stat3 inhibitor, AP-1 inhibitor or 
both. HB-EGF FL promoter reporter activity is significantly diminished after treating of both 
Stat3 inhibitor and AP-1 inhibitor (Figure 4.15). These results indicate that AP-1 and Stat3 medi-
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ated HB-EGF promoter activity through this region (-1022 to -682) and are the major transcrip-
tion factors stimulating HB-EGF promoter activity.  
 
4.4.4 Proximal AP-1 and Stat3 binding elements are required for HB-EGF activity in 
LIV-1 overexpressing cells. 
 
To investigate the specific binding sites of AP-1 and Stat3 were required for the HB-EGF 
promoter activity, we used computer analysis to identify consensus AP-1 and Stat3 binding sites 
in the -1022 to -682 region of HB-EGF promoter sequence. A potential Stat3 binding site located 
at -945 and two potential AP-1 binding sites locate at -846 and -745 (Figure 4.16). We intro-
duced site-specific mutations into the FL promoter reporter construct at one Stat3 and two AP-1 
sites. The mutations we chose were according to published paper which showed successful 
blocking AP-1 and Stat3 binding and the desired mutations were confirmed by DNA sequencing 
(Figure 4.17). We then transfected FL wild type, mut stat3, mut AP-1 site1, and mut AP-1 site2 
into LIV-1 overexpressing cells and control cells. Mut Stat3 and mut AP-1 site1 promoter re-
porter constructs showed reduced promoter reporter activity similar to previous results treating 
by inhibitors (Figure 4.18). However, mut AP-1 site2 still displayed approximately the same ac-
tivity comparing to the wild type. We also used Stat3 and AP-1 inhibitors to treat the cells trans-
fected with mut stat3 and mut AP-1 site promoter reporter constructs to further confirmed the 
mutant constructs no longer response to the inhibitors (data not shown). Furthermore, we gener-
ated a double mutant which had both mutations of Stat3 and AP-1 site1 and then transfected into 
LIV-1 overexpressing cells and control cells. Clearly, the double mutant promoter construct al-
most lost of promoter activity (Figure 4.19). These results suggested that Stat3 (-945) and AP-1(-
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846) binding elements are required for the activation of Hb-EGF promoter in LIV-1 overexpress-
ing cells. 
 
4.4.5 AP-1 and phosphor-stat3 bind to HB-EGF promoter in vivo. 
 
The previous results suggested the role of AP-1 and Stat3 in stimulation of HB-EGF 
promoter activity. To further examine the binding of AP-1 and Stat3 to HB-EGF promoter in vi-
vo, we performed ChIP assays by using c-Jun and phosphor-Stat3 antibodies in LIV-1 overex-
pressing cells and control cells. Both anti-c-Jun and anti-phospho-Stat3 antibodies did precipitate 
significant higher amount of the HB-EGF promoter in LIV-1 overexpressing cells comparing to 
control ones (Figure 4.20 A&B). We also used anti-RNA polymerase II antibody and mouse IgG 
to immunoprecipitate the GAPDH promoter as a positive and a negative control (Figure 4.20 C). 
In addition, we treated the Stat3 inhibitor to LIV-1 overexpressing cells and control cells and did 
the ChIP experiment by using an anti-phospho-Stat3 antibody and anti-c-Jun antibody. The Stat3 
inhibitor significantly reduced the amount of HB-EGF precipitated by anti-phospho-Stat3 anti-
bodies (Figure 4.21A). Additionally, the Stat3 inhibitor did not affect HB-EGF promoter precipi-
tated by anti-c-Jun antibodies (Figure 4.21B). The similar ChIP experiments were also carried 
out by treating AP-1 inhibitors in LIV-1 overexpressing cells and control cells and probing with 
an anti-c-Jun antibody and anti-phospho-Stat3 antibody. Similarly, the AP-1 inhibitor diminished 
the amount of HB-EGF precipitated by anti-phospho-c-Jun antibodies (Figure 4.22A) and the 
AP-1 inhibitor did not affect HB-EGF promoter precipitated by anti-phospho-Stat3 antibodies 
(Figure 4.22B). We also included a ChIP experiment by using anti-RNA polymerase II as a con-
trol to show the specificity of the inhibitors (Figure 4.23). 
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Figure 4.1 
MMP 2/9 inhibitors reduced the EGFR and downstream ERK and Stat3 signaling. LIV-1 over-
expressing cells and control cells were treated by MMP inhibitor for 0, 2 and 5 hours. Phospho-
EGFR activity was decrease as well as p-ERK and p-Stat3. 
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Figure 4.2 
HB-EGF mRNA expression was increased in LIV-1 overexpressing cells. RT-PCR showed that 
LIV-1 overexpressing cells expressed much more HB-EGF transcript but not EGF. GAPDH was 
used as a control. 
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Figure 4.3 
HB-EGF promoter activity is significantly increased in LIV-1 overexpressing cells. HB-EGF 
promoter firefly luciferase reporter was transfected into LIV-1 overexpressing cells and control 
cells. LIV-1 overexpressing cells showed 4-5 fold of increase in HB-EGF promoter activity. 
Renilla luciferase reporter was used as a internal control and all the results were normalized with 
Renilla activity. 
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Figure 4.4 
The signaling pathways in LIV-1 overexpressing cells. Western bloting showed that LIV-1 over-
expressing cells have constitutively activated phospho-EGFR and activated downstream p-ERK 
and p-Stat3 signaling. 
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Figure 4.5 
Different drugs were used to examine the importance of each signaling pathway. HB-EGF pro-
moter was transfected into LIV1#8 and con1 and then treated with U0126 (10uM), SB203580 
(10uM) or stat3 inhibitor (2uM). The result showed that both U0126 and stat3 inhibitor sup-
pressed HB-EGF promoter activity but not SB203580. 
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Figure 4.6 
Inhibition of ERK and Stat3 signalings suppressed HB-EGF mRNA expression in vivo. LIV-1 
overexpressing cells and control cells were treated with U0126 (10uM) or stat3 inhibitor (2uM) 
for 8 hours. RT-PCR showed that both U0126 and stat3 inhibitor suppressed HB-EGF transcript. 
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Figure 4.7 
AP-1 is one of the major transcription factors downstream of ERK signaling. LIV-1 overexpress-
ing cells and control cells were transfected with AP-1 response element-luc reporter with or 
without treatment of AP-1 inhibitor. Renilla reporter was an internal control and the results were 
normalized with Renilla reporter activity. 
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Figure 4.8 
Inhibition of AP-1 reduced HB-EGF promoter activity in LIV-1 overexpressing cells. LIV-1 
overexpressing cells and control cells were transfected with HB-EGF promoter reporter with or 
without treatment of AP-1 inhibitor. Renilla reporter was an internal control and the results were 
normalized with Renilla reporter activity. 
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Figure 4.9 
ERK and AP-1 acted in the same pathway. LIV-1 overexpressing cells and control cells were 
transfected with HB-EGF promoter reporter and treated with AP-1 inhibitor, U0126 or both. 
Renilla reporter was an internal control and the results were normalized with Renilla reporter ac-
tivity.  
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Figure 4.10 
Overexpression of constitutive active Stat3 stimulated HB-EGF promoter activity in ARCaPE 
cells. ARCaP E cells were co-transfected with HB-EGF promoter reporter and Stat3 constitutive 
active or dominant negative expression vector. Renilla reporter was an internal control and the 
results were normalized with Renilla reporter activity. 
 
 
 
 
 
 
 
 
0 
1 
2 
3 
4 
5 
6 
- stat3 C stat3 DN 
ARCaPE 
Fi
re
fly
:R
en
ill
a 
L
uc
ife
ra
se
 R
at
io
 
138 
 
Figure 4.11 
Blockade of AP-1 and Stat3 suppressed HB-EGF promoter activity in LIV-1 overexpressing 
cells. LIV-1 overexpressing cells and control cells were transfected with HB-EGF promoter re-
porter and treated with Stat3 inhibitor, AP-1 inhibitor, or both. Renilla reporter was an internal 
control and the results were normalized with Renilla reporter activity. 
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Figure 4.12 
Treatment of AP-1 and Stat3 inhibitors inhibited HB-EGF mRNA expression. LIV-1 overex-
pressing cells and control cells were treated with AP-1(10uM), stat3 inhibitor (2uM) or both for 
8 hours. HB-EGF mRNA expression level was determined by RT-PCR. 
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Figure 4.13 
HB-EGF promoter deletion constructs. 
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Figure 4.14 
Stat3 reponse elements lied between -1022 to -681. ARCaP E cells were co-transfected with 3 
different length of HB-EGF promoter reporter and Stat3 constitutive active or dominant negative 
expression vector. Renilla reporter was an internal control and the results were normalized with 
Renilla reporter activity. 
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Figure 4.15 
Only full length HB-EGF responded to the treatment of Ap-1 and Stat3 inhibitors. LIV-1 over-
expressing cells and control cells were transfected with 3 different length of HB-EGF promoter 
reporter and treated with Stat3 inhibitor, AP-1 inhibitor, or both. Renilla reporter was an internal 
control and the results were normalized with Renilla reporter activity. 
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Figure 4.16 
Site-derected mutagenesis of HB-EGF promoter reporter constructs. 
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Figure 4.17 
DNA sequencing results of site-directed mutagenic constructs. 
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Figure 4.18 
Mutation of AP-1 or Stat3 binding sites decreased HB-EGF promoter activity. LIV-1 overex-
pressing cells and control cells were transfected with 4 different HB-EGF promoter reporter- FL 
wild type, Stat3 mutant, AP-1 site 1 mutant, or AP-1 site2 mutant. Renilla reporter was an inter-
nal control and the results were normalized with Renilla reporter activity. 
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Figure 4.19 
Mutation of both AP-1 and Stat3bind sites abrogated HB-EGF promoter activity. LIV-1 overex-
pressing cells and control cells were transfected with 4 different HB-EGF promoter reporter- FL 
wild type, Stat3 mutant, AP-1 site 1 mutant or Stat3 and AP-1 site1 double mutant. Renilla re-
porter was an internal control and the results were normalized with Renilla reporter activity. 
 
 
 
 
 
 
0 
2 
4 
6 
8 
10 
12 
LIV1#8 LIV1#14 con1 con2 
Fi
re
fly
: R
en
ill
a 
L
uc
ife
ra
se
 a
ct
iv
ity
 R
at
io
 
FL 
Mut Stat3 
Mut AP-1 site1 
Mut AP-1 site1+stat3 
147 
 
Figure 4.20 
Stat3 and c-Jun interact with HB-EGF promoter in vivo. (A), Chromatin immunoprecipitations 
(ChIP) of the HB-EGF promoter by phospho-Stat3 antibody in LIV-1 overexpressing cells and 
control cells. (B), c-Jun antibody. (C), ChIP of the GAPDH promoter by RNA polymerase II or 
mouse IgG were used as a positive or negative control. Real-time PCR was performed to deter-
mine the quantitative binding of HB-EGF promoter. All the results were normalized with input 
GAPDH. 
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Figure 4.21 
Stat3 inhibitor decreases of Stat3 interacting with HB-EGF promoter. (A), Chromatin 
immunoprecipitations (ChIP) of the HB-EGF promoter by phospho-Stat3 antibody in LIV-1 
overexpressing cells and control cells treated with or without Stat3 inhibitor. (B), c-Jun antibody. 
Real-time PCR was performed to determine the quantitative binding of HB-EGF promoter. All 
the results were normalized with input GAPDH. 
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Figure 4.22 
AP-1 inhibitor decreases of AP-1 interacting with HB-EGF promoter. (A), Chromatin 
immunoprecipitations (ChIP) of the HB-EGF promoter by c-Jun antibody in LIV-1 overexpress-
ing cells and control cells treated with or without c-Jun inhibitor. (B), Stat3 antibody. Real-time 
PCR was performed to determine the quantitative binding of HB-EGF promoter. All the results 
were normalized with input GAPDH. 
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Figure 4.23 
ChIP of the GAPDH promoter in LIV-1 overexpressing cells and control cells treated with Stat3 
inhibitor or AP-1 inhibitor by RNA polymerase II was used as a positive control. Real-time PCR 
was performed to determine the quantitative binding of HB-EGF promoter. All the results were 
normalized with input GAPDH. 
 
 
 
 
 
 
 
 
 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
LIV1#8 LIV1#14 con1 con2 
Fo
le
 d
iff
er
en
ce
 
(N
or
m
al
iz
e 
w
ith
 G
A
PD
H
) 
 
IP: pol II 
- 
Stat3 inhibitor 
AP-1 inhibitor 
151 
5 DISCUSSION 
Using the well-characterized ARCaP human prostate cancer progression model, we found 
that LIV-1 is involved in the promotion of prostate cancer cell EMT, local growth and distant 
metastases.  This conclusion is based on the following evidences, 1) the induction of EMT by 
IGF-1 or TGF-β1 in ARCaPE cells was accompanied by an elevated LIV-1 expression (Figures 
2.1 and 2.2); 2) LIV-1 expression was elevated in the isogenic cells expressing mesenchymal 
phenotype, i.e. higher LIV-1 expression was found in ARCaPM than ARCaPE cells (Figures 2.3, 
2.6 and 2.16); 3) overexpression of LIV-1 in ARCaPE cells promoted an irreversible EMT of the-
se cells, leading to increased local growth and distant metastases to bone and soft tissues (Figures 
2.9-2.15); 4) certain EMT-inducing growth factors, such as β2-M, could both activate LIV-1 ex-
pression and promote bone and soft tissue metastases in prostate, breast, lung and renal cancer 
cells (Josson et al.); and 5) selected repression of LIV-1 in ARCaPM cells was accompanied by a 
reversal of EMT, causing ARCaPM to adopt a phenotype similar to that of the ARCaPE cells with 
decreased migration and invasion (Figures 2.3-2.5).  In addition, the function of LIV-1 in the 
promotion of aggressive cancer behaviors is also supported by the data obtained from the anal-
yses of a large number of clinical prostate cancer specimens (Figures 2.17 and 2.18). 
Prostate cancer cells in metastasized tumors are known to display both epithelial and 
mesenchymal phenotypes in morphology and expression profile, and metastatic prostate tumors 
are likely comprised of heterogeneous populations of both epithelial and mesenchymal cells.  
With regard to the mechanism of interconversion between epithelial and mesenchymal pheno-
types through EMT and MET, it is interesting to note that an increased LIV-1 expression can be 
achieved by hormonal induction (El-Tanani and Green, 1997; McClelland et al., 1998) and by 
growth factor engagement (Figure 2.1).  It is conceivable that with induction of LIV-1, cancer 
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cells can establish metastatic foci through EMT that confers increased migratory and invasive 
capabilities.  Inside the tumor metastasis, LIV-1 expression may be subsided once the inducer 
withdraws, leading to tumor colonization with cancer cells resuming epithelial morphology and 
marker expression. 
Our study also supports that ARCaP cell EMT is highly reliable and robust as a predic-
tive model for EMT and prostate cancer progression (Zhau et al., 2008).  We validated in clinical 
human prostate cancer specimens that the level of LIV-1 was progressively elevated from nor-
mal/benign to PIN in the primary and to metastatic cancer, with the highest expression found in a 
majority of bone metastases.  LIV-1 seems to have a mediatory role, downstream from growth 
factor signaling in the promotion of prostate cancer EMT under experimental conditions, and 
likely this role also manifested in clinical progression of prostate cancer cells (Figures 2.17 and 
2.18).  LIV-1 is thus a candidate marker for prostate cancer progression and metastasis.  Sup-
pression of LIV-1 expression and blockade of its role in EMT may be warrant for further clinical 
investigation as a novel therapeutic approach of cancer growth and metastasis. 
By examining large numbers of clinical specimens for both epithelial and mesenchymal 
stromal markers, it is interesting to notice that tumor cells detected in the bone are predominately 
epithelial (data not shown).  It seems that metastatic tumor is comprised of highly heterogeneous 
cancer cell population.  Alternatively, these results raised the possibility that EMT and MET 
transitions in metastatic prostate cancer do not necessarily involve a perfect concordance of cell 
morphology, gene expression and behavioral profiles.  Thus, a metastatic tumor may express in-
herent epithelial genes simultaneously with acquired mesenchymal biomarkers, but the acquired 
mesenchymal phenotype underscores the increased aggressive and invasive behaviors. 
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The close correlation between LIV-1 level and cancer progression documented in the 
clinical specimens is likely a general phenomenon in prostate cancer.  Several factors may con-
tribute to abnormally enhanced LIV-1 expression during prostate cancer progression and metas-
tasis.  It has been shown that LIV-1 expression is negatively regulated by intracellular zinc con-
centration (Chowanadisai et al., 2008; Taylor et al., 2003), which provides an auto-regulatory 
negative feedback (Chowanadisai et al., 2008).  Prostate tumor cells are frequently observed with 
a lowered intracellular zinc pool (Bataineh et al., 2002; Costello et al., 2005; Franklin et al., 
2005b), which may induce LIV-1 expression.  Additionally, loss of intracellular zinc may pre-
vent cancer cells from apoptotic death, since a lowered zinc level can alter mitochondrial mem-
brane potential to hamper the release of apoptosis-triggering caspases (Truong-Tran et al., 2001).  
On the other hand, LIV-1 expression may also be stimulated by growth factors in the tumor mi-
croenvironment, since treatment with TGFα, TGF-β1, EGF, IGF-1 and β2-M all enhanced the 
LIV-1 level (el-Tanani and Green, 1996, 1997; Zhau et al., 2008).  However, no direct evidence 
shows that LIV-1 overexpression by genomic or epigenomic mechanisms lead to cancer progres-
sion. We reported recently that β2-M-mediated signaling could lead to a decreased intracellular 
iron which drives EMT and cancer lethality to bone and soft tissues (Josson et al.).  Currently it 
is not clear if LIV-1 is involved in an autoregulatory loop in the regulation of intracellular zinc 
and iron.  In this study, we did not find differences of intracellular total zinc or labile zinc con-
centrations between LIV-1 overexpressed and neo-control ARCaPE cells, suggesting that LIV-1 
overexpression did not affect intracellular zinc pool in prostate cancer cells.  Additional studies 
should be carried out to determine the role of LIV-1 in determining zinc transport in other pros-
tate cancer cell lines. 
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Growth factor regulation by LIV-1 is mediated by the activation of Stat3 transcription 
factor (Yamashita et al., 2004), which orchestrate the nuclear translocation of several important 
pleiotropic transcription factors.  LIV-1 was shown to increase Snail transcription, translation 
and translocation to cell nucleus in zebrafish organizer (Yamashita et al., 2004).  Among many 
of the common downstream transcription factors responsive to the pleiotropic signals, Snail 
functions to drive EMT (Huber et al., 2005).  By directly repressing E-cadherin transcription, 
Snail decreases cellular polarity and cell-cell junctional communication, and promotes EMT in 
not only cancer cells, but also in normal cells as seen in wound healing and renal fibrosis (Batlle 
et al., 2000; Cano et al., 2000; Karreth and Tuveson, 2004; Yang et al., 2004).  EMT plays a piv-
otal role in cell motility during embryonic development (Thiery, 2002), and breast cancer cells 
undergoing EMT can gain stem cell-like properties with increased ability for self renewal as de-
termined by anchorage-independent growth (Radisky and LaBarge, 2008).  The link between 
EMT and stem cell-like properties could have important implications for the development of 
novel therapeutic approaches for cancer.  In this regard, the relationship between Snail and LIV-
1 expression has been reported in breast, cervical and pancreatic cancer progression and lymph 
node metastases (Manning et al., 1995; Manning et al., 1994; McClelland et al., 1998; Unno et 
al., 2009; Zhao et al., 2007a).  On the other hand, pathophysiologic functions of LIV-1 may be 
influenced by the background of the cells being studied.  It remains unclear why in some breast 
cancer cell lines, LIV-1 expression has been associated with the suppression of E-cadherin while 
in other cells LIV-1 knockdown paradoxically increased the invasiveness (Shen et al., 2009). 
LIV-1 expression has been reported to be mediated by Stat3 (Yamashita et al., 2004) and 
our studies showed that LIV-1 could further stimulate Stat3 activation (Figure 4.1). Activation of 
Stat3 enhanced LIV-1 expression and overexpression of LIV-1 could evoke more Stat3 activa-
155 
tion, suggesting a positive feedback loop exists. Aberrant Stat3 signaling has been frequently ob-
served in different types of human cancers such as prostate, breast, pancreas, brain, lung, and 
head and neck cancer (Bowman et al., 2000; Catlett-Falcone et al., 1999; Coffer et al., 2000; 
Garcia et al., 2001; Lin et al., 2000; Song and Grandis, 2000). Constitutively activated Stat3 has 
been demonstrated to be able to induce transformation, and associated with tumor development 
and progression (Bowman et al., 2000). Studies have shown that Stat3 functioned in mediating 
cell proliferation, angiogenesis, and preventing apoptosis (Sinibaldi et al., 2000; Yu and Jove, 
2004).  Because of its important role in tumorigenesis, Stat3 has been used as a new anticancer 
target. Studies in cell culture and animal models established that Stat3 is a promising therapeutic 
target in a variety of human cancers (Bowman et al., 2000; Turkson and Jove, 2000). Inhibition 
of Stat3 signaling has been demonstrated repeatedly to cause growth inhibition and apoptosis in 
tumor cells harboring constitutive active Stat3 (Catlett-Falcone et al., 1999; Lin et al., 2000). 
Since LIV-1 overexpression was associated with the development of larger prostate tu-
mors (Figures 2.13-2.15) and with accelerated proliferation in vitro (data not shown), we carried 
out mechanistic analyses to elucidate the underlying regulatory pathway.  LIV-1 overexpressing 
clones expressed high levels of HB-EGF (Figures 3.8 and 3.10).  At the same time, these clones 
produced significantly increased MMP2 and MMP9 transcripts (Figure 3.8) as well as their en-
zymatic activities (Figure 3.9).  The enzymatic activities are involved in catalyzing HB-EGF 
shedding (Figures 3.10).  The soluble form of HB-EGF may have interacted with EGFR to cause 
the constitutive EGFR phosphorylation (Figure 3.11).  EGFR phosphorylation will lead to ERK-
mediated signaling transduction, which favors cell growth and facilitate cellular motility.  In ad-
dition, ERK-mediated signaling may promote EMT by downregulating E-cad expression, thus 
releasing β-catenin from cytoplasmic membrane to enter the nucleus, where β-catenin interacts 
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with T cell-factor/lymphoid enhancer factor (LEF)  transcription factors to promote the growth 
and survival of cancer cells (Spaderna et al., 2007). 
By further examining HB-EGF promoter activity, we found that HB-EGF promoter activ-
ity was significantly increased in LIV-1 overexpressing cells (Figure 4.3) and HB-EGF promoter 
activity was mediated by both AP-1 and Stat3 transcription factors (Figures 4.8 and 4.11). ChIP 
experiments suggested that AP-1 and Stat3 regulated HB-EGF promoter through directly binding 
to proximal promoter regions in vivo (Figure 4.20). Inhibition AP-1 and Stat3 activity or muta-
tion of AP-1 and Stat3 binding sequences led to completely abrogate HB-EGF promoter activity 
(Figures 4.15 and 4.18). The HB-EGF expression is increased in a lot of different cancer types 
(Freeman et al., 1998; Ito et al., 2001a; Ito et al., 2001b; Ito et al., 2001c; Ito et al., 2001d; Kra-
mer et al., 2007; Tanaka et al., 2005). HB-EGF expression was shown to be several to hundred 
fold higher than other EGFR ligands in ovarian and bladder cancer patients (Miyamoto et al., 
2004; Thogersen et al., 2001), indicating the critical role of HB-EGF in mediating EGFR activa-
tion at least in ovarian and bladder cancers. 
  Constitutively active Stat3 has often been found in many tumors, suggesting its im-
portant role in tumorigenesis. In addition, Stat3-mediated HB-EGF promoter is not restricted to 
LIV-1 overexpressing cells, since overexpression of constitutive active form of Stat3 in HEK 
cells also stimulated HB-EGF promoter activity, suggesting a universal role in regulating HB-
EGF promoter. However, more detail studies need to be done to comfirm the critical role of Stat3 
in regulating HB-EGF gene expression in other types of tumors.   
Our results as described herein emphasize a coordinated regulation of LIV-1 expression 
during the EMT of prostate cancer cells which ultimately gain increased migratory, invasive and 
metastastic potential.  LIV-1 expression increased EGFR-ERK signaling, through the shedding 
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of HB-EGF from cell surface, by a concomitant induction of MMP2 and MMP9 proteolytic en-
zymes, which cleave the membrane-bound HB-EGF, and the soluble HB-EGF is responsible for 
the EGFR phosphorylation and downstream ERK signaling.  In addition, both AP-1 and Stat3 
controlled HB-EGF gene expression. Both AP-1 and Stat3 are important oncogenic transcription 
factors found in many tumors. Furthermore, constitutive EGFR activation is a common oncogen-
ic signal in prostate cancer as well as in other malignancies.  Our study established a close link 
for the first time between LIV-1 expression and EGFR-ERK signaling which drives EMT and 
prostate cancer migration, invasion and metastases.  LIV-1 could be a new biomarker and a new 
therapeutic target for prostate cancer progression and metastasis. 
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